Theralink (THER) 10-K 25 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 17, 2020	Jun. 28, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	OncBioMune Pharmaceuticals, Inc
Entity Central Index Key	0001362703
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 1,360,910
Entity Common Stock, Shares Outstanding		881,118
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash	$ 21,489	$ 201
Prepaid expenses and other current assets	40,664	215,681
Total Current Assets	62,153	215,882
OTHER ASSETS:
Property and equipment, net	1,966	4,304
Right-of-use asset, net	23,686
Security deposit	6,400	6,400
Total Assets	94,205	226,586
CURRENT LIABILITIES:
Convertible debt, net	2,915,297	1,434,252
Notes payable	538,875	538,875
Accounts payable	620,042	550,296
Accrued liabilities	1,554,473	884,035
Lease payable - current	23,686
Derivative liabilities	9,320,052	3,364,032
Due to related parties	372,685	315,466
Liabilities of discontinued operations	686,547	686,547
Total Current Liabilities	16,031,657	7,773,503
Total Liabilities	16,031,657	7,773,503
Commitments and contingencies (Note 9)
STOCKHOLDERS' DEFICIT:
Preferred stock value
Common stock: $0.0001 par value, 6,666,667 shares authorized; 835,215 and 330,216 issued and outstanding at December 31, 2019 and 2018, respectively	84	33
Common stock issuable: 22,828 commons stock issuable as of December 31, 2019 and 2018	2	2
Additional paid-in capital	10,652,370	9,640,711
Accumulated deficit	(26,589,908)	(17,187,664)
Total Stockholders' Deficit	(15,937,452)	(7,546,917)
Total Liabilities and Stockholders' Deficit	94,205	226,586
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value
Total Stockholders' Deficit
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value		1
Total Stockholders' Deficit		$ 1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	26,667	26,667
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	6,666,667	6,666,667
Common stock, shares issued	835,215	330,216
Common stock, shares outstanding	835,215	330,216
Common stock issuable, shares	22,828	22,828
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,333	1,333
Preferred stock, shares issued	1,333	1,333
Preferred stock, shares outstanding	1,333	1,333
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,523	10,523
Preferred stock, shares issued	3,856	10,523
Preferred stock, shares outstanding	3,856	10,523

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES:
Professional fees	566,216	594,611
Compensation expense	846,240	804,527
Research and development expense	166,720	204,562
General and administrative expenses	189,393	174,273
Total Operating Expenses	1,768,569	1,777,973
LOSS FROM OPERATIONS	(1,768,569)	(1,777,973)
OTHER INCOME (EXPENSE):
Interest expense	(1,795,398)	(2,130,838)
Derivative (expense) income	(5,760,902)	8,229,168
(Loss) gain on debt extinguishment	(77,375)	2,114,335
Gain (loss) on foreign currency transactions		33,633
Total Other Income (Expense)	(7,633,675)	8,246,298
NET INCOME (LOSS)	(9,402,244)	6,468,325
COMPREHENSIVE INCOME (LOSS):
Net income (loss)	(9,402,244)	6,468,325
Other comprehensive gain (loss):
Unrealized foreign currency translation gain (loss)		(25,184)
Comprehensive income (loss)	$ (9,402,244)	$ 6,443,141
NET INCOME (LOSS) PER COMMON SHARE
Basic	$ (19)	$ 20.66
Diluted	$ (19)	$ 9.09
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	494,843	311,811
Diluted	494,843	708,704

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Deficit - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Gain [Member]	Total
Balance at Dec. 31, 2017		$ 1	$ 21	$ 2	$ 8,821,803	$ (23,655,989)	$ 25,184	$ (14,808,978)
Balance, shares at Dec. 31, 2017	1,333	10,523	205,088	22,028
Common stock issued for services					52,500			52,500
Common stock issued for services, shares			3,333
Accretion of stock options					276,918			276,918
Common stock issuable for cash and subscription receivable pursuant to subscription agreements					6,000			6,000
Common stock issuable for cash and subscription receivable pursuant to subscription agreements,shares				800
Common stock issued upon cashless warrant exercise			$ 4		(4)
Common stock issued upon cashless warrant exercise, shares			43,620
Common stock issued upon conversion of convertible debt and interest and settlement expense			$ 8		483,494			483,502
Common stock issued upon conversion of convertible debt and interest and settlement expense, shares			78,175
Foreign currency translation adjustment							(25,184)	(25,184)
Net income (loss)						6,468,325		6,468,325
Balance at Dec. 31, 2018		$ 1	$ 33	$ 2	9,640,711	(17,187,664)		(7,546,917)
Balance, shares at Dec. 31, 2018	1,333	10,523	330,216	22,828
Accretion of stock options					140,697			140,697
Common stock issued, at fair value, upon conversion of convertible debt and interest			$ 51		871,461			871,512
Common stock issued, at fair value, upon conversion of convertible debt and interest, shares			508,999
Redemption of Series B Preferred		$ (1)			(499)			(500)
Redemption of Series B Preferred, shares		(6,667)
Net income (loss)						(9,402,244)		(9,402,244)
Balance at Dec. 31, 2019			$ 84	$ 2	$ 10,652,370	$ (26,589,908)		$ (15,937,452)
Balance, shares at Dec. 31, 2019	1,333	3,856	839,215	22,828

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS USED IN OPERATING ACTIVITIES
Net income (loss)	$ (9,402,244)	$ 6,468,325
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	2,338	2,338
Stock-based compensation	140,697	329,418
Amortization of debt discount	1,434,148	1,465,057
Derivative expense (income)	5,760,902	(8,229,168)
Loss (gain) on debt extinguishment	77,375	(2,360,146)
Non-cash default interest on debt	(179,989)	94,286
Gain on foreign currency transactions		(25,184)
Change in operating assets and liabilities:
Prepaid expenses and other current assets	175,017	(202,995)
Accounts payable	69,746	172,069
Liabilities of discontinued operations		(8,449)
Accrued liabilities and other liabilities	750,879	615,043
NET CASH USED IN OPERATING ACTIVITIES	(1,171,131)	(1,679,406)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party advances, net	57,219	53,882
Proceeds from convertible debt, net of cost	1,135,700	2,034,143
Repayment of convertible debt		(415,849)
Redemption of Series B Preferred	(500)
Proceeds from sale of common stock and subscription receivable		6,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,192,419	1,678,176
NET INCREASE (DECREASE) IN CASH	21,288	(1,230)
CASH, beginning of the period	201	1,431
CASH, end of the period	21,489	201
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	6,023	243,885
Income taxes
Non-cash investing and financing activities:
Issuance of common stock for convertible debt and interest	436,781	427,612
Increase in debt discount and derivative liabilities	552,473	2,039,143
Debt issue cost	260,340
Non-cash amortization of right-of-use asset	$ 35,530

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Organization OncBioMune Pharmaceuticals, Inc. (the “Company”) is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to attack its own cancer while not attacking the patient’s healthy cells. The Company has proprietary rights to an immunotherapy platform with an initial focus on prostate and breast cancers but that may be used to fight any solid tumor. The Company is also developing targeted therapies. Our mission is to improve overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment. We believe our technology is safe, and utilizes clinically proven research methods of treatment to provide optimal likelihood of patient recovery. On March 10, 2017 (the “Closing Date”), the Company completed the acquisition of 100% of the issued and outstanding capital stock of Vitel Laboratorios, S.A. de C.V., a Mexican variable stock corporation (“Vitel”) from its shareholders Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie (collectively, the “Vitel Stockholders”) pursuant to the terms and conditions of a Contribution Agreement to the Property of Trust F/2868 entered into among the Company and the Vitel Stockholders on the Closing Date (the “Contribution Agreement”). The Company acquired Vitel for the purpose of commercializing the Company’s ProscaVax™ vaccine technology and cancer technologies in Mexico, Central and Latin America and to utilize Vitel’s distribution network and customer and industry relationships. On December 29, 2017, the Board of Directors of the Company determined to sell or otherwise dispose of its interest in Vitel and OncBioMune México due to disputes with the original Vitel Stockholders and resulting loss of operational control of the assets and operations of Vitel and OncBioMune Mexico. Accordingly, Vitel and OncBioMune México were treated as a discontinued operation through December 31, 2017 and were deconsolidated effective January 1, 2018 (see Note 3). The Company expects to terminate the Contribution Agreement and Trust Agreement during 2020. On April 3, 2019, the Company filed an amendment to its Articles of Incorporation to increase its authorized common stock from On August 6, 2019, the Company filed an amendment to its Articles of Incorporation to increase its authorized common stock from On August 28, 2019, the Company filed an amendment to its Articles of Incorporation to implement a reverse stock split of the Company’s issued and outstanding shares of common and preferred stock at a ratio of 1-for-750 (the “Reverse Stock Split”), which became effective on All share and per share amounts in the accompanying historical consolidated financial statements have been retroactively adjusted to reflect the Stock Split (see Note 9).

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and principals of consolidation The Company’s consolidated financial statements include the financial statements of OncBioMune Pharmaceuticals, Inc. and its wholly-owned subsidiaries, OncBioMune, Inc. for all periods presented. Vitel and Oncbiomune México, S.A. De C.V. (from March 10, 2017 to December 31, 2017) were treated as a discontinued operation through December 31, 2017 and were deconsolidated effective January 1, 2018 (see Note 3). All significant intercompany accounts and transactions have been eliminated in consolidation. Going concern The consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying consolidated financial statements, the Company had net income (loss) of $(9,402,244) and $6,468,325 for the years ended December 31, 2019 and 2018, respectively, however the net income in 2018 resulted primarily from the change in fair value of derivative liabilities. The net loss from operations were $1,768,569 and $1,777,973 for the years ended December 31, 2019 and 2018, respectively. The net cash used in operations were $1,171,131 and $1,679,406 for the years ended December 31, 2019 and 2018, respectively. Additionally, the Company had an accumulated deficit of $26,589,908 and $17,187,664, at December 31, 2019 and 2018, respectively, had a stockholders’ deficit of $15,937,452 at December 31, 2019, had a working capital deficit of $15,969,504 at December 31, 2019. The Company had no revenues from continuing operations for the years ended December 31, 2019 and 2018, and we defaulted on our debt. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. Management cannot provide assurance that we will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that our capital resources are not currently adequate to continue operating and maintaining its business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and/or equity financings to fund its operations in the future and is seeking potential candidates for a merger or acquisition. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the years ended December 31, 2019 and 2018 include the valuation of liabilities of discontinued operations, useful life of property and equipment, valuation of operating lease right-of-use (“ROU”) assets and liabilities, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances, the fair value of non-cash equity transactions and the valuation of derivative liabilities. Concentrations Generally, the Company relies on one vendor as a single source of raw materials to produce certain components of its cancer treatment products. Any production shortfall that impairs the supply of the antigen in ProscaVax™ to the Company could have a material adverse effect on the Company’s business, financial condition and results of operations. If the Company is unable to obtain a sufficient quantity of antigen, there could be a substantial delay in successfully developing a second source supplier. Fair value of financial instruments and fair value measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on December 31, 2019. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, due from and to related parties, prepaid expenses, accounts payable and accrued liabilities approximate their fair market value based on the short-term maturity of these instruments. Assets or liabilities measured at fair value or a recurring basis included embedded conversion options in convertible debt and included warrants (see Note 6 and Note 9) and were as follows at December 31, 2019 and 2018: At December 31, 2019 At December 31, 2018 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative liabilities — — 9,320,052 — — 3,364,032 A roll forward of the level 3 valuation financial instruments is as follows: For the Year Ended December 31, 2019 2018 Balance at beginning of year $ 3,364,032 $ 11,966,760 Initial valuation of derivative liabilities included in debt discount 552,473 2,039,143 Initial valuation of derivative liabilities included in derivative income (expense) 22,546 1,811,617 Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon conversion of debt (357,355 ) (422,835 ) Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon cashless exercise of warrants — (666,756 ) Reclassification of derivative liabilities to gain (loss) on debt extinguishment for debt settlement — (1,323,111 ) Change in fair value included in derivative income (expense) 5,738,356 (10,040,786 ) Balance at end of year $ 9,320,052 $ 3,364,032 ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. Cash and cash equivalents For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At December 31, 2019 and 2018, the Company did not have any cash equivalents. The Company maintains its cash in bank and financial institution deposits that at times may exceed federally insured limits. There were no balances in excess of FDIC insured levels as of December 31, 2019 and 2018. The Company has not experienced any losses in such accounts through December 31, 2019. Property and equipment Property are stated at cost and are depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Impairment of long-lived assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. For the years ended December 31, 2019 and 2018, the Company did not record any impairment loss. Derivative liabilities The Company has certain financial instruments that are embedded derivatives associated with capital raises and certain warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10 – Derivative and Hedging – Contract in Entity’s Own Equity In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. These amendments simplify the accounting for certain financial instruments with down-round features. The amendments require companies to disregard the down-round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. The guidance was adopted as of January 1, 2019 and the Company elected to record the effect of this adoption retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the consolidated balance sheet as of the beginning of 2019, the period which the amendment is effective. The Company adopted ASU No. 2017-11 in the first quarter of 2019, and the adoption did not have any impact on its consolidated financial statement and there was no cumulative effect adjustment. Revenue recognition In May 2014, FASB issued an update Accounting Standards Update, ASU 2014-09, establishing ASC 606 - Revenue from Contracts with Customers. ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017, requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. The Company adopted this standard on January 1, 2018 using the modified retrospective approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Based on an evaluation of the impact ASU 2014-09 will have on the Company’s sources of revenue, the Company has concluded that ASU 2014-09 did not have any impact on the process for, timing of, and presentation and disclosure of revenue recognition from customers and there was no cumulative effect adjustment. The Company does not have revenues from continuing operations for the years ended December 31, 2019 and 2018. Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Through March 31, 2018, pursuant to ASC 505-50 - Equity-Based Payments to Non-Employees, all share-based payments to non-employees, including grants of stock options, were recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black Scholes valuation model, the Company periodically reassessed the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and the Company adjusts the expense recognized in the consolidated financial statements accordingly. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions by expanding the scope of the stock-based compensation guidance in ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU No. 2018-07 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but entities may not adopt prior to adopting the new revenue recognition guidance in ASC 606. The Company early adopted ASU No. 2018-07 in the second quarter of 2018, and the adoption did not have any impact on its consolidated financial statements. Income taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes Research and development Research and development costs incurred in the development of the Company’s products are expensed as incurred. For the years ended December 31, 2019 and 2018, research and development costs were $166,720 and $204,562, respectively, and are included in operating expenses on the accompanying consolidated statements of operations. Basic and diluted loss per share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of December 31, 2019 and 2018 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: December 31, 2019 2018 Stock warrants 73.443.404 190,913 Convertible debt 59,751,203 — Stock options 41,600 29,600 Series A preferred stock 1,333 — Series B preferred stock 3,856 — 133,241,396 220,513 The following table presents a reconciliation of basic and diluted net loss per share: Years Ended December 31, 2019 2018 Income (loss) per common share — basic: Net income (loss) $ (9,402,244 ) $ 6,468,325 Weighted average common shares outstanding — basic 494,843 311,811 Net income (loss) per common share — basic: $ (19.00 ) $ 20.66 Income (loss) per common share — diluted: Income (loss) from continuing operations $ (9,402,244 ) $ 6,468,325 Add: interest on debt 1,795,398 2,130,838 Less: derivative income and debt settlement income 5,838,277 (10,343,503 ) Less: gain on foreign currency transactions — (33,633 ) Numerator for loss from continuing operations per common share — diluted (1,768,569 ) (1,777,973 ) Weighted average common shares outstanding — basic 494,843 311,811 Effect of dilutive securities: Preferred shares — 11,857 Warrants — 61,293 Convertible notes payable — 323,743 Weighted average common shares outstanding – diluted 494,843 708,704 Net loss per common share — diluted: $ (19.00 ) $ 9.09 Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On January 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating lease ROU assets represents the right to use the leased asset for the lease term Recent accounting pronouncements In August 2018, the FASB issued ASU 2018-13 —Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement Removals 1. The amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy 2. The policy for timing of transfers between levels 3. The valuation processes for Level 3 fair value measurements 4. For nonpublic entities, the changes in unrealized gains and losses for the period included in earnings for recurring Level 3 fair value measurements held at the end of the reporting period. Modifications 1. In lieu of a roll forward for Level 3 fair value measurements, a nonpublic entity is required to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. 2. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. 3. The amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. Additions 1. The changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period. 2. The range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. In addition, the amendments eliminate at a minimum an entity shall disclose at a minimum Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited consolidated financial statements.

Acquisition, Discontinuation of

Acquisition, Discontinuation of Operations and Deconsolidation of Vitel and Oncbiomune Mexico	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Acquisition, Discontinuation of Operations and Deconsolidation of Vitel and Oncbiomune Mexico	NOTE 3 – ACQUISITION, DISCONTINUATION OF OPERATIONS AND DECONSOLIDATION OF VITEL AND ONCBIOMUNE MEXICO Acquisition of Vitel In connection with a business acquisition in 2017, the Company issued 81,544 unregistered shares of its common stock and 6,667 shares of Series B preferred stock which primarily gives the holder voting rights. The acquired company was deconsolidated on January 1, 2018 (see below). On February 20, 2019, pursuant to the Certificate of Designation, the Company exercised its right to redeem all of the 6,667 shares of the Series B Preferred outstanding held by to Banco Actinver, S.A., in its capacity as Trustee of a Trust Agreement for the benefit of Mr. Cosme and Mr. Alaman equal to the stated value. The total redemption price equaled $500 which was equal to $0.075 per share of Series B Preferred (see Note 9 “Series B Preferred Shares”). Discontinuation of Operations and Deconsolidation of Vitel On December 29, 2017, the Board of Directors of the Company determined to sell or otherwise dispose of its interest in Vitel and OncBioMune Mexico due to disputes with the original Vitel Stockholders and resulting loss of operational control of the assets and operations of Vitel and OncBioMune Mexico. Accordingly, Vitel and OncBioMune Mexico are now treated as a discontinued operation for all periods presented in accordance with ASC 205-20. At December 31, 2018 and after deconsolidation, the Company has recorded the liabilities of these subsidiaries that existed at December 31, 2017 as a contingent liability and therefore reflected liabilities of discontinued operation of $686,547 on the accompanying consolidated balance sheet, which consist of accounts payable balances incurred through December 31, 2017. Pursuant to ASC Topic 205-20, Presentation of Financial Statements - Discontinued Operations, the business of the OncBioMune Mexico and Vitel are now considered discontinued operations because of management’s decision of December 29, 2017. The assets and liabilities classified as discontinued operations in the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2019 and 2018 is set forth below. December 31, 2019 2018 Assets: Current assets: Cash $ — $ — Total current assets — — Total assets $ — $ — Liabilities: Current liabilities: Accounts payable $ 686,547 $ 692,592 Due to related parties — 432 Payroll liabilities — 1,972 Total current liabilities 686,547 694,996 Total liabilities $ 686,547 $ 694,996

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 4 — PROPERTY AND EQUIPMENT At December 31, 2019 and 2018, property and equipment consisted of the following: Useful Life 2019 2018 Leasehold improvements 5 Years $ 10,976 $ 10,976 Furniture and equipment 5 Years 13,715 13,715 24,691 24,691 Less: accumulated depreciation (22,725 ) (20,387 ) Property and equipment, net $ 1,966 $ 4,304 For the years ended December 31, 2019 and 2018, depreciation and amortization expense amounted to $2,338 and $2,338, respectively.

Operating Lease Right-of-use ('

Operating Lease Right-of-use ('ROU') Assets and Operating Lease Liabilities	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Operating Lease Right-of-use ("ROU") Assets and Operating Lease Liabilities	NOTE 5 – OPERATING LEASE RIGHT-OF-USE (“ROU”) ASSETS AND OPERATING LEASE LIABILITIES In September 2015, the Company entered into a lease agreement for its corporate facility in Baton Rouge, Louisiana. The lease is for a period of 60 months commencing in September 2015 and expiring in August 2020. Pursuant to the lease agreement, the lease requires the Company to initially pay a monthly base rent of $3,067 plus a pro rata share of operating expenses beginning September 2015 and shall increase, beginning September 2018, to a monthly base rent of $3,200 plus a pro rata share of operating expenses. In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs (see Note 2). In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $59,216. For the year ended December 31, 2019, lease costs amounted to $49,137 which included base lease costs of $38,400 and common area and other expenses of $10,737, all of which were expensed during the period and included in general and administrative expenses on the accompanying consolidated statements of operations. The significant assumption used to determine the present value of the lease liability was a discount rate of 10% which was based on the Company’s estimated incremental borrowing rate. Right-of-use asset (“ROU”) is summarized below: December 31, 2019 Operating office lease $ 59,216 Less accumulated reduction (35,530 ) Balance of ROU asset as of December 31, 2019 $ 23,686 Operating lease liability related to the ROU asset is summarized below: December 31, 2019 Operating office lease $ 59,216 Total lease liabilities 59,216 Reduction of lease liability (35,530 ) Total as of December 31, 2019 23,686 Future base lease payments under the non-cancelable operating lease at December 31, 2019 are as follows: Period ending Amount August 31, 2020 25,600 Total minimum non-cancelable operating lease payments 25,600 Less: discount to fair value (1,914 ) Total lease liability at December 31, 2019 $ 23,686

Convertible Debt

Convertible Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Debt	NOTE 6 – CONVERTIBLE DEBT November 2016 Financing On November 23, 2016, the Company entered into Amended and Restated Securities Purchase Agreements (the “Amended and Restated Securities Purchase Agreements”) with three institutional investors (the “Purchasers”) for the sale of the Company’s convertible notes and warrants. Pursuant to the Amended and Restated Securities Purchase Agreements, the Company issued upon closing to the Purchasers for an aggregate subscription amount of $350,000, (i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes (the “November 2016 Notes”) and (ii) warrants (the “Warrants”) to purchase aggregate of 3,111 shares of the Company’s common stock at an initial exercise price of $131.25 (subject to adjustments under certain conditions as defined in the Warrants) (see below for reduction of warrant exercise price) which are exercisable for a period of five years from November 23, 2016. The aggregate principal amount of the November 2016 Notes was $350,000 and the Company received $300,000 after giving effect to the original issue discount of $50,000. The November 2016 Notes bore interest at a rate equal to 10% per annum (which interest rate increased to 24% per annum upon the occurrence of an Event of Default (as defined in the November 2016 Notes)), had a maturity date of July 23, 2017 and were convertible (principal, and interest) at any time after the issuance date into shares of the Company’s common stock at an initial conversion price equal to $112.50 per share (subject to adjustment as provided in the Note) (see below for reduction for reduction of conversion price), provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the November 2016 Notes were convertible and the November 2016 Warrants shall be exercisable at 60% of the lowest closing price during the prior twenty trading days of the common stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). Due to non-payment of the November 2016 Notes, an event of default occurred and accordingly, the November 2016 Notes and Warrants are convertible and exercisable based on the default terms. On May 23, 2017, in connection with the November 2016 Notes, the Company entered into forbearance agreements (the “Forbearance Agreements”) with the Purchases whereby the Purchasers waived any event of default, as defined in the November 2016 Notes. The Company failed to make a payment on May 23, 2017 to each of the Holders as required pursuant to the November 2016 Notes which resulted in an event of default under such Notes. As of result of the event of default, the aggregate amount owing under the November 2016 Notes as of May 23, 2017 was increased to $509,135 with such amount including a mandatory default amount of $141,299 and accrued interest of $17,836 resulting in debt settlement expense of $141,299 which was recorded in May 2017. The Forbearance Agreements also provide for the Holders to forbear their right to demand an immediate cash payment of the principal amount due plus accrued interest as a result of the Company’s failure to satisfy its payment obligations to the Holder on May 23, 2017 so long as the Company complies with its other obligations under the November 2016 Notes and the other transaction documents. The Forbearance Agreements did not waive the default interest rate of 24%. In consideration therefore, and as currently set forth in the November 2016 Notes, the Holders shall be entitled to convert such notes from time to time at their discretion in accordance with the terms of the November 2016 Notes and the November 2016 Notes shall not be subject to repayment unless agreed to by the Holder of such Note. In connection with the Forbearance Agreements, in May 2017, the Company increased the principal balance of the November 2016 Notes by $159,135, reduced accrued interest payable by $17,836, and recorded debt settlement expense of $141,299. In 2017, the Company also increased the principal amount of these notes by $42,327 and charged this to interest expense for other default charges and other expenses. In 2017, the Purchasers converted $369,423 and $32,878 of outstanding principal and interest, respectively, of the November 2016 Notes into 11,150 shares of common stock. In 2018, the Purchasers fully converted the remaining outstanding principal and interest of $139,712 and $21,869, respectively, of the November 2016 Notes into 17,372 shares of the Company’s common stock. The November 2016 Notes had no outstanding balance as of December 31, 2018. The November 2016 Notes and related Warrants includes; (i) down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception; and (ii) default conversion and exercise price provisions where, the November 2016 Notes shall be convertible and the November 2016 Warrants shall be exercisable at 60% of the lowest closing price during the prior twenty trading days of the common stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). Subsequent to the date of these November 2016 Notes, the Company sold stock at a share price of $56.25 per share then $37.50 per share and then $7.50 per share. Accordingly, pursuant to these ratchet provisions, the conversion price on the November 2016 Notes were lowered to $37.50 per share then to $22.50 per share and then to $4.50 per share and the exercise price of the November 2016 Warrants was lowered to $4.50. Additionally, the total number of November 2016 Warrants were increased on a full ratchet basis from 3,111 warrants to 42,346 warrants, an increase of 39,235 warrants (see Note 9). In September 2017, the Company issued 12,729 shares of its common stock upon the cashless exercise of 12,099 of these warrants (see Note 9). As of December 31, 2019, there were 30,247 warrants outstanding under the November 2016 Warrants. June 2017 Financing On June 2, 2017, the Company entered into a Securities Purchase Agreement (the “Second Securities Purchase Agreement”) with the Purchasers for the sale of the Company’s convertible notes and warrants. Pursuant to the terms provided for in the Second Securities Purchase Agreement, the Company issued the Purchasers for an aggregate subscription amount of $233,345: (i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes (the “June 2017 Notes”); and (ii) warrants (the “June 2017 Warrants”) to purchase an aggregate of 2,074 shares of the Company’s common stock at an initial exercise price of $131.25 (subject to adjustments under certain conditions as defined in the June 2017 Warrants) and exercisable for five years after the issuance date. The aggregate principal amount of the June 2017 Notes was $233,345 and the Company received $190,000 after giving effect to the original issue discount of $33,345 and $10,000 of offering costs. The June 2017 Notes bear interest at a rate equal to 10% per annum (which interest rate is increased to 24% per annum upon the occurrence of an Event of Default (as defined in the June 2017 Notes)), have a maturity date of February 2, 2018 and are convertible (principal and interest) at any time after the issuance date, into shares of the Company’s common stock at an initial conversion price equal to $112.50 per share (subject to adjustment as provided in the June 2017 Notes), provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the June 2017 Notes shall be convertible and the June 2017 Warrants shall be exercisable at 60% of the lowest closing price during the prior twenty trading days of the common stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). The June 2017 Notes are currently in default. The June 2017 Notes provide for two amortization payments on the six-month, seven-month and eight-month anniversary of the issue date with each amortization payment being one third of the total outstanding principal and interest. If the six-month amortization payment is made in cash then the payment is an amount equal to 120% of the applicable amortization payment and if the seven-month or the eight-month amortization payments are made in cash then the payment is an amount equal to 125% of the applicable amortization payment. The June 2017 Notes may be prepaid at any time until the 180th day following the Original Issue Date at an amount equal to (i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the June 2017 Notes and accrued and unpaid interest during months four through six following the Original Issue Date. In order to prepay the June 2017 Notes, the Company shall provide 20 Trading Days prior written notice to the Holder, during which time the Holder may convert the June 2017 Notes in whole or in part at the Conversion Price. During the nine months ended June 30, 2018, the Company also increased the principal amount of these notes by $2,268 for other default charges and other expenses. In 2018, the Purchasers converted $118,786 and $7,036 outstanding principal and interest, respectively, of the June 2017 Notes into 19,819 shares of the Company’s common stock. In addition, pursuant a securities purchase agreement dated September 24, 2018, the Company purchased back from one Purchaser, a June 2017 Note with $37,814 and $4,534 of outstanding principal and interest, respectively, (see- Puritan Settlement Agreement The June 2017 Notes and related June 2017 Warrants includes; (i) down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception; and (ii) default conversion and exercise price provisions where, the June 2017 Notes shall be convertible and the June 2017 Warrants shall be exercisable at Default Conversion Price as defined above. Subsequent to the date of these June 2017 Notes, the Company sold stock at a share price of $37.50 per share and then $7.50 per share. Accordingly, pursuant to these ratchet provisions, the conversion price of the notes were lowered to $4.50 per shares and the exercise price of the June 2017 Warrants were lowered to $4.50 per share and the total number of June 2017 Warrants were increased on a full ratchet basis from 2,074 warrants to 60,497 warrants, an increase of 58,423 warrants (see Note 9). In 2018, the Company issued 11,332 shares of its common stock upon the cashless exercise of 12,099 of the June 2017 Warrants and 8,066 of these warrants were purchased back from the lender (see- Puritan Settlement Agreement July 2017 Financing On July 26, 2017, the Company entered into a Securities Purchase Agreement (the “Third Securities Purchase Agreement”) with the Purchasers for the sale of the Company’s convertible notes and warrants. Pursuant to the terms provided for in the Third Securities Purchase Agreement, the Company issued to the Purchasers for an aggregate subscription amount of $300,000: (i) 10% Original Issue Discount 5% Senior Secured Convertible Notes in the aggregate principal amount of $333,883 (the “July 2017 Notes”); and (ii) warrants (the “July 2017 Warrants”) to purchase an aggregate of 6,359 shares of the Company’s common stock at an exercise price of $75.00 per share (subject to adjustments under certain conditions as defined in the Warrants). The July 2017 Notes were issued on July 26, 2017. The July 2017 Notes bear interest at a rate equal to 5% per annum (which interest rate is increased to 24% per annum upon the occurrence of an Event of Default (as defined in the July 2017 Notes)), have a maturity date of March 25, 2018 and are convertible (principal, and interest) at any time after the issuance date into shares of the Company’s common stock at a conversion price equal to $52.50 per share (subject to adjustment as provided in the July 2017 Notes), provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the July 2017 Notes shall be convertible and the July 2017 Warrants shall be exercisable at 60% of the lowest closing price during the prior twenty trading days of the common stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). The July 2017 Notes are currently in default. The July 2017 Notes provide for three amortization payments on the six-month, seven-month and eight-month anniversary of the issue date with each amortization payment being one third of the total outstanding principal and interest. If the six-month amortization payment is made in cash then the payment is an amount equal to 110% of the applicable amortization payment and if the seven-month or the eight-month amortization payments are made in cash then the payment is an amount equal to 115% of the applicable amortization payment. The July 2017 Notes may be prepaid at any time until the 210th day following the Original Issue Date at an amount equal to (i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the July 2017 Notes and accrued and unpaid interest during months four through seven following the Original Issue Date. In order to prepay the July 2017 Notes, the Company shall provide 20 Trading Days prior written notice to the Purchaser, during which time the Purchaser may convert the July 2017 Notes in whole or in part at the Conversion Price. During the year ended December 31, 2018, the Purchasers converted $111,295, $11,414 and $47,028 of outstanding principal, accrued interest and default interest, respectively, of the July 2017 Notes into 31,053 shares of common stock. In addition, pursuant to a securities purchase agreement dated September 24, 2018, the Company purchased back, from one Purchaser, a July 2017 Note with $155,812 and $38,395 of outstanding principal and interest, respectively (see- Puritan Settlement Agreement On June 5, 2018, the original purchaser of the July 2017 Notes entered into an Assignment Agreement (“First Note Assignment”) with the assignee (“First Assignee”) for the sale of a portion of the July 2017 Notes (“First Assigned Note”) with outstanding principal of $111,295 and accrued interest of $29,180. In connection with the First Note Assignment, a default interest in the amount of $53,733 was charged, which was included in the sale price and updated principal of the First Assigned Note totaling $194,208. On October 16, 2018, the First Assignee, in turn entered into an Assignment Agreement (“Second Note Assignment”) with another assignee (“Second Assignee”) for the sale of the First Assigned Note with outstanding principal of $194,208 and accrued interest of $3,204. In connection with the Second Note Assignment, a prepayment premium of $49,353 was charged which was included in the sale price and updated principal of $246,765. In 2018, the Purchasers converted $17,500 of the outstanding principal of the new Note (“Second Assigned Note”), into 4,818 shares of common stock. During the quarter ended September 30, 2019, the default interest charged on June 2018 of $53,733 and prepayment premium charged on October 2018 of $49,535, an aggregate penalty of $103,268, was contested by the Company and the penalties related to these note assignments were removed from the outstanding principal balance of the Second Assigned Note. In addition, certain amounts of the accrued liabilities had been previously included in the principal balance of $32,384 was reversed and a new accrued interest based in the agreed upon principal balance was accrued which totaled $30,612. During the year ended December 31, 2019, the Purchaser converted $65,140 of outstanding principal, of the Second Assigned Note, into 106,622 shares of common stock. As of December 31, 2019, the Second Assigned Note (July 2017 Notes) had an outstanding principal balance of $28,655 and accrued interest of $32,372. The July 2017 Notes and related Warrants includes; (i) down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception; and (ii) default conversion and exercise price provisions where, the July 2017 Notes shall be convertible and the July 2017 Warrants shall be exercisable at the Default Conversion Price as define above. Subsequent to the date of these July 2017 Notes, the Company sold stock at a share price of $37.50 per share and then at $7.50 per share. Accordingly, pursuant to these ratchet provisions, the conversion price of the July 2017 Notes was lowered to $4.50 per share and the exercise price of the July 2017 Warrants was lowered to $4.50 per share and the total number of July 2017 Warrants was increased on a full ratchet basis from 6,359 warrants to 105,994 warrants, an increase of 99,635 warrants (see Note 9). In 2018, the Company issued 32,289 shares of its common stock upon the cashless exercise of 35,332 of these warrants. As of December 31, 2019, there were 70,662 warrants outstanding under the July 2017 Warrants. January 2018 Financing On January 29, 2018, the Company entered into a Securities Purchase Agreement (the “Fourth Securities Purchase Agreement”) with the Purchasers for the sale of the Company’s convertible notes and warrants. Pursuant to the terms provided for in the Fourth Securities Purchase Agreement, the Company issued to the Purchasers for an aggregate subscription amount of $333,333: (i) 10% Original Issue Discount 5% Senior Secured Convertible Notes in the aggregate principal amount of $333,333 (the “January 2018 Notes”); and (ii) 5 year warrants (the “January 2018 Warrants”) to purchase an aggregate of 11,111 shares of the Company’s common stock at an exercise price of $30.00 per share (subject to adjustments under certain conditions as defined in the Warrants). The closing under the Fourth Securities Purchase Agreement occurred on January 29, 2018. The aggregate principal amount of the January 2018 Notes is $333,333 and the Company received $295,000 after giving effect to the original issue discount of $33,333 and offering costs of $5,000. These January 2018 Notes bear interest at a rate equal to 5% per annum (which interest rate is increased to 18% per annum upon the occurrence of an Event of Default (as defined in the January 2018 Notes)), have a maturity date of September 29, 2018 and are convertible (principal, and interest) at any time after the issuance date into shares of the Company’s common stock at a conversion price equal to $22.50 per share (subject to adjustment as provided in the January 2018 Notes), provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the January 2018 Notes shall be convertible and the January 2018 Warrants shall be exercisable at 60% of the lowest closing price during the prior twenty trading days of the common stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). The January 2018 Notes are currently in default. The January 2018 Notes provide for three amortization payments on the six-month, seven-month and eight-month anniversary of the original issue date with each amortization payment being one third of the total outstanding principal and interest. If the six-month amortization payment is made in cash, then the payment is an amount equal to 110% of the applicable amortization payment and if the seven-month or the eight-month amortization payments are made in cash then the payment is an amount equal to 115% of the applicable amortization payment. The January 2018 Notes may be prepaid at any time until the 180th day following the Original Issue Date at an amount equal to (i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the five months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the January 2018 Notes and accrued and unpaid interest during the six month following the Original Issue Date. In order to prepay the January 2018 Notes, the Company shall provide 20 Trading Days prior written notice to the Purchaser, during which time the Purchaser may convert the January 2018 Notes in whole or in part at the Conversion Price. Pursuant to a securities purchase agreement dated September 24, 2018, the Company purchased back, from one Purchaser, a January 2018 Note with $111,111 and $98,031 outstanding principal and interest, respectively (see- Puritan Settlement Agreement The January 2018 Notes and related Warrants includes; (i) down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception; and (ii) default conversion and exercise price provisions where, the January 2018 Notes shall be convertible and the January 2018 Warrants shall be exercisable at the Default Conversion Price as defined above. The total number of January 2018 Warrants were increased on a full ratchet basis from 11,111 warrants to 4,367,376, an aggregate increase of 4,356,265 warrants (see Note 9). Pursuant to a securities purchase agreement dated September 24, 2018, the Company purchased back, from one Purchaser, warrants to purchase 10,078 (post anti-dilution) of the Company’s common stock (see- Puritan Settlement Agreement March 2018 Financing On March 13, 2018, the Company entered into a Securities Purchase Agreement (the “Fifth Securities Purchase Agreement”) securities with the Purchasers for the sale of the Company’s convertible notes and warrants. Pursuant to the terms provided for in the Fifth Purchase Agreement, the Company issued for an aggregate subscription amount of $333,333: (i) 10% Original Issue Discount 5% Senior Secured Convertible Notes in the aggregate principal amount of $333,333 (the “March 2018 Notes”) and (ii) warrants (the “March 2018 Warrants”) to purchase an aggregate of 16,667 shares of the Company’s common stock at an exercise price of $30.00 per share. The aggregate principal amount of the March 2018 Notes is $333,333 and as of the date the Company received $61,000 after giving effect to the original issue discount of $33,333 and offering costs of $10,000 which are treated as a debt discount, the payment of legal and accounting fees of $29,000 not related to March 2018 Notes and the funding of an escrow account held by an escrow agent of $200,000. The March 2018 Notes bear interest at a rate of 5% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in the March 2018 Notes)), have a maturity date of November 13, 2018 and the principal and interest are convertible at any time at a conversion price equal to $15.00 per share (subject to adjustment as provided in the March 2018 Notes); provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the March 2018 Notes shall be convertible and the March 2018 Warrants shall be exercisable at 60% of the lowest closing price during the prior twenty trading days of the common stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). The March 2018 Notes are currently in default. The March 2018 Notes provide for amortization payments on each of the six-month anniversary of the issue date, seven-month anniversary of the issue date and on the maturity date with each amortization payment being one third of the total outstanding principal and all interest accrued as of the payment date. If the six-month amortization payment is made in cash then the Company shall pay the holder 110% of the applicable amortization payment and if the seven-month or the maturity date amortization payments are made in cash then the Company shall pay the holder 115% of the applicable amortization payment. The holder may elect at its option to receive the amortization payments in common stock subject to certain equity conditions. The March 2018 Notes may be prepaid at any time until the 180th day following the original issue date at an amount equal to (i) 115% of outstanding principal balance of the Note and accrued and unpaid interest through the five month anniversary of the issue date, and (ii) 120% of outstanding principal balance of the Notes and accrued and unpaid interest from the fifth month anniversary of the issue date through the six month anniversary of the issue date. In order to prepay the March 2018 Notes, the Company shall provide 20 trading days prior written notice to the holders, during which time a holder may convert its March 2018 Notes in whole or in part at the conversion price. Pursuant to a securities purchase agreement dated September 24, 2018, the Company purchased back, from one Purchaser, a convertible note with $111,111 and $97,383 outstanding principal and accrued interest, respectively (see- Puritan Settlement Agreement The March 2018 Notes and related March 2018 Warrants includes; (i) down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception; and (ii) default conversion and exercise price provisions where, the March 2018 Notes shall be convertible and shall be exercisable at the Default Conversion Price as defined above. Pursuant to a securities purchase agreement dated September 24, 2018, the Company purchased back, from one Purchaser, warrants to purchase 15,117 (post anti-dilution) of the Company’s common stock (see- Puritan Settlement Agreement July 2018 Financing On July 25, 2018, the Company entered into a securities purchase agreement (the “Sixth Securities Purchase Agreement”) with an institutional investor for the sale of a convertible note in the aggregate principal amount of $150,000 (the “July 2018 Note”). The July 2018 Note bears interest at 8% per year and matures on July 24, 2019. The July 2018 Note is convertible into common stock at a 25% discount to the average of the closing prices of the common stock for the prior five trading days including the date upon which a notice of conversion is received by the Company or its transfer agent. The holder will not have the right to convert any portion of its note if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to its conversion. The July 2018 Note may be prepaid at the Company’s option at a 105% premium between 30 days and 180 days after issuance, and at a 110% premium between 180 days after issuance and the maturity date. Upon certain events defined in the note as “sale events”, the holder may demand repayment of the note for 125% of the principal plus accrued but unpaid interest. The note also includes certain penalties upon the occurrence of an event of default, including an increase in the principal and reduction in the conversion rate, as further described in the July 2018 Note. The Company agreed to use its best efforts to file a proxy statement and take all necessary corporate actions in order to obtain shareholder approval to increase its authorized shares of common stock or effect a reverse split to allow for reserving sufficient shares of common stock to allow for full conversion of the July 2018 Note. As of December 31, 2019, the July 2018 Note is in default, and accruing interest at 24% and had outstanding principal and accrued interest of $150,000 and $26,342, respectively. September 2018 Financing On September 24, 2018, the Company entered into a securities purchase agreement (the “Seventh Purchase Agreement” and together with the Amended and Restated Purchase Agreements and the Second, Third, Fourth, Fifth and Sixth Purchase Agreement, the “Securities Purchase Agreements”) with four accredited investors (the “Seventh Round Purchasers” and together with the Purchasers, the “Note Purchasers”) for the sale of the Company’s convertible notes and warrants. Pursuant to the Seventh Purchase Agreement, the Company issued to the Seventh Round Purchasers for an aggregate subscription amount of $1,361,111; (i) 10% Original Issue Discount 5% Senior Convertible Notes in the aggregate principal amount of $1,361,111 (the “September 2018 Notes”) and (ii) 5 year warrants (the “September 2018 Warrants”) to purchase an aggregate of 68,056 shares of the Company’s common stock at an exercise price of $30.00 per share (subject to adjustments under certain conditions as defined in the September 2018 Warrants). The Company received $1,181,643 in aggregate net proceeds from the sale, net of $136,111 original issue discount and $43,357 in legal fees. The September 2018 Notes bear interest at a rate of 5% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in the September 2018 Notes)), had a maturity date of May 24, 2019 and the principal and interest are convertible at any time at a conversion price equal to $15.00 per share (subject to adjustment as provided in the September 2018 Notes); provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the September 2018 Notes shall be convertible and the September 2018 Warrants shall be exercisable at 60% of the lowest closing price during the prior twenty trading days (the “Default Conversion Price”). The September 2018 Notes are currently in default. The September 2018 Notes provide for amortization payments on each of the six-month anniversary of the issue date, seven-month anniversary of the issue date and on the maturity date with each amortization payment being one third of the total outstanding principal and all interest accrued as of the payment date. If the six-month amortization payment is made in cash then the Company shall pay the holder 110% of the applicable amortization payment and if the seven-month or the maturity date amortization payments are made in cash then the Company shall pay the holder 115% of the applicable amortization payment. The holder may elect at its option to receive the amortization payments in common stock subject to certain equity conditions. The Notes may be prepaid at any time until the 180th day following the original issue date at an amount equal to (i) 115% of outstanding principal balance of the note and accrued and unpaid interest through the five month anniversary of the issue date, and (ii) 120% of outstanding principal balance of the notes and accrued and unpaid interest during month six following the original issuance date of the notes. In order to prepay the notes, the Company shall provide 20 trading days prior written notice to the holders, during which time a holder may convert its note in whole or in part at the conversion price. During the year ended December 31, 2019, the Purchasers converted $58,073 and $28,234 outstanding principal and accrued interest, respectively, of the September 2018 Notes into 39,934 shares of the Company’s common stock. As of December 31, 2019, the September 2018 Notes had outstanding principal and accrued interest of $1,303,038 and $149,283, respectively. The initial exercise price of the September 2018 Warrants is $30.00 per share, subject to adjustment as described below, and are exercisable for five years after the issuance date. The September 2018 Warrants are exercisable for cash at any time and are exercisable on a cashless basis at any time there is no effective registration statement registering the shares of common stock underlying the warrants. The exercise price of the warrants is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upo

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	NOTE 7 – NOTES PAYABLE From June 2017 to September 2017, the Company entered into loan agreements with several third parties (the “Loans”). Pursuant to the loan agreements, the Company borrowed an aggregate principal amount of $538,875. The Loans bear interest at an annual rate of 33.3%, are unsecured and are in default. As of December 31, 2019, and 2018, loan principal due to these third parties amounted to $538,875 for both periods. At December 31, 2019 and 2018, interest payable related to these Loans amounted to $430,223 and $250,777, respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 8 – RELATED PARTY TRANSACTIONS Due to related parties From time to time, the Company receives advances from and repays such advances to the Company’s former chief executive officer for working capital purposes and to repay indebtedness. For the years ended December 31, 2019 and 2017, due to related party activity consisted of the following: Total Balance due to related parties at December 31, 2017 $ (261,584 ) Working capital advances received (264,185 ) Repayments made 210,303 Balance due to related parties at December 31, 2018 $ (315,466 ) Working capital advances received (57,219 ) Repayments made — Balance due to related parties at December 31, 2019 $ (372,685 )

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Equity (Deficit)	NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT) On April 3, 2019, the Company filed an amendment to its Articles of Incorporation to increase its authorized common stock from 500,000,000 shares to 1,500,000,000 shares (see Note 1). The Company’s 1,520,000,000 authorized shares consisted of 1,500,000,000 shares of common stock at $0.0001 per share par value, and 20,000,000 shares of preferred stock at $0.0001 per share par value. On August 6, 2019, the Company filed an amendment to its Articles of Incorporation to increase its authorized common stock from 1,500,000,000 shares to 5,000,000,000 shares (see Note 1). The Company’s 5,020,000,000 authorized shares consist of 5,000,000,000 shares of common stock at $0.0001 per share par value, and 20,000,000 shares of preferred stock at $0.0001 per share par value. On August 28, 2019, the Company filed an amendment to its Articles of Incorporation to implement a reverse stock split of the Company’s issued and outstanding shares of common and preferred stock at a ratio of 1-for-750 (the “Reverse Stock Split”), which became effective on All share and per share amounts in the accompanying historical consolidated financial statements have been retroactively adjusted to reflect the Stock Split (see Note 1). Series A Preferred Stock On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,333 shares of the authorized 26,667 Preferred Stock as Series A Preferred Stock. Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action. As of December 31, 2019, of these shares, 667 are held by a former Chief Executive Officer and a current member of our Board of Directors and 666 shares are held by a former member of our Board of Directors. Series B Preferred Stock On March 7, 2017, the Company filed a certificate of designation, preferences and rights of Series B preferred stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to designate 10,523 shares of its previously authorized preferred stock as Series B preferred stock, par value $0.0001 per share and a stated value of $0.0001 per share. The Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series B preferred stock are entitled to dividends or distributions share for share with the holders of the Common Stock, if, as and when declared from time to time by the Board of Directors. The holders of shares of Series B preferred stock have the following voting rights: ● Each share of Series B preferred stock entitles the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders. ● Except as otherwise provided in the Certificate of Designation, the holders of Series B preferred stock, the holders of Company common stock and the holders of shares of any other Company capital stock having general voting rights and shall vote together as one class on all matters submitted to a vote of the Company’s stockholders; and ● Commencing at any time after the date of issuance of any shares of the Series B Preferred Stock (the “Issuance Date”) and upon the earliest of the occurrence of (i) a holder of the Series B Preferred Stock owning, directly or indirectly as a beneficiary or otherwise, shares of Common Stock which are less than 5.0% of the total outstanding shares of Common Stock, (ii) the date a holder of the Series B Preferred Stock is no longer an employee of the Company or any of its subsidiaries or (iii) five years after the Issuance Date, the Company shall have the right to redeem all of the then outstanding Series B Preferred Stock held by such holder at a price equal to the Stated Value (the “Redemption Price”). The Series B Preferred Stock which is redeemed as provided for in the Certificate of Designations shall be returned to the Company (and, if not so returned, shall automatically be deemed canceled). The Redemption Price shall be mailed to such holder at the holder’s address of record, and the Series B Preferred Stock owned by such holder shall be canceled. In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Corporation, the holders of the Series B Preferred Stock shall be entitled to receive, share for share with the holders of shares of Common Stock and Series A Preferred Stock, all the assets of the Corporation of whatever kind available for distribution to stockholders, after the rights of the holders of the Series A Preferred Stock have been satisfied. In March 2017, the Company issued 3,856 shares of Series B Preferred to Jonathan F. Head, Ph. D, the Company’s Chief Executive Officer and a member of the Board of Directors of the Company as provided for in the Contribution Agreement and was recorded as compensation expense. In addition, in March 2017 the Company issued 6,667 shares of Series B Preferred to Banco Actinver for the benefit of the Vitel Stockholders as partial consideration in the exchange for 100% of the issued and outstanding capital stock of Vitel. (see Note 3). On February 20, 2019, pursuant to the Certificate of Designation, the Company exercised its right to redeem 6,667 shares of the Series B Preferred outstanding held by to Banco Actinver, S.A., in its capacity as Trustee of the Trust Agreement for the benefit of Mr. Cosme and Mr. Alaman equal to the stated value. The total redemption price equaled $500 or $0.075 per share of Series B Preferred. As of December 31, 2019, and 2018, there were 3,856 and 10,523 shares of Series B Preferred issued and outstanding, respectively. Common Stock Common stock issuable for cash ● During the year ended December 31, 2018, the Company had 800 shares of its common stock issuable to an investor for cash proceeds of $6,000, or $7.50 per share, pursuant to a unit subscription agreement. Shares issued for services ● During the year ended December 31, 2018, the Company issued 3,333 shares of its common stock with a grant date value of $52,500 or $15.75 per share as reported on the OTC Pink on the grant date, in exchange for legal services, pursuant to an agreement. Shares issued for debt conversion ● During the year ended December 31, 2018, the Company issued 78,175 shares of its common stock upon the conversion of principal note balances of $387,292, interest of $40,320, and default interest of $55,890. ● During the year ended December 31, 2019, the Company issued 508,999 shares of its common stock upon the conversion of principal note balances of $356,339, accrued interest of $44,308 and default interest of $36,134. These shares of common stock had an aggregate fair value $871,512 and the difference between the aggregate fair value and the aggregate converted amount of $436,281 resulted in a loss on debt extinguishment of $434,731. Shares issued for cashless exercise of warrants ● During the year ended December 31, 2018, the Company issued 43,620 shares of its common stock upon the cashless exercise of 47,431 of its warrants (see Note 6). Warrants Warrants issued pursuant to equity subscription agreements In 2016, in connection with the sale of common stock, the Company issued an aggregate of 1,295 five-year warrants to purchase common shares for an exercise price of $225 per common share to investors pursuant to unit subscription agreements. As of December 31, 2019, and 2018, 1,292 of these warrants were issued and outstanding for both periods. In 2017, in connection with the sale of common stock, the Company issued an aggregate of 6,169 five-year warrants to purchase common shares for an exercise price of $225 per common share to investors pursuant to unit subscription agreements. As of December 31, 2019, and 2018, 6,169 of these warrants were issued and outstanding for both periods. Warrants issued pursuant to Securities Purchase Agreements The warrants detailed below, issued pursuant to the Securities Purchase Agreements (see Note 6), have initial exercise price between $0.20 and $131 (subject to adjustments under certain conditions as defined in the agreements) and includes a down-round provision under which the exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception. It also includes a default provision pursuant to which, these Warrants shall be exercisable at the Default Conversion Price as defined in the related Notes (see Note 6). As of December 31, 2019, there were not enough authorized shares to allow the issuance of common stock if all the warrants need to be exercised. Outstanding warrants as of December 31, 2019, all of which have been accounted for as derivative liabilities, are summarized as follows: Original Cumulative Anti-dilution Expired, Warrants Agreement Total Outstanding Exercise Warrants related to the 2016 subscription agreements 1,295 — (3 ) — — 1,292 $ 225.00 Warrants related to the 2017 subscription agreements 6,169 — — — — 6,169 $ 225.00 November 2016 Warrants 3,111 39,235 — — (12,099 ) 30,247 $ 4.50 June 2017 Warrants 2,074 58,423 — (8,067 ) (12,099 ) 40,331 $ 4.50 July 2017 Warrants 6,359 99,635 — — (35,332 ) 70,662 $ 4.50 January 2018 Warrants 11,111 4,356,265 — (10,078 ) — 4,357,298 $ 0.05 March 2018 Warrants 16,667 6,534,399 — (15,117 ) — 6,535,949 $ 0.05 September 2018 Warrants 68,056 39,964,625 — — — 40,032,681 $ 0.05 November 2018 Warrants 6,389 3,751,781 — — — 3,758,170 $ 0.05 March 2019 Warrants 2,778 1,631,209 — — — 1,633,987 $ 0.05 April 2019 Warrants I 1,389 815,605 — — — 816,994 $ 0.05 April 2019 Warrants II 10,264 6,027,318 — — — 6,037,582 $ 0.05 May 2019 Warrants 500 293,618 — — — 294,118 $ 0.05 June 2019 Warrants I 6,458 3,792,562 — — — 3,799,020 $ 0.05 June 2019 Warrants II 5,556 1,628,431 — — — 1,633,987 $ 0.05 July 2019 Warrants I 5,556 1,628,431 — — — 1,633,987 $ 0.05 July 2019 Warrants II 5,556 1,628,431 — — — 1,633,987 $ 0.05 August 2019 Warrants 2,778 — — — — 2,778 $ 15.00 September 2019 Warrants 16,667 — — — — 16,667 $ 15.00 November 2019 Warrants I 277,500 — — — — 277,500 $ 0.20 November 2019 Warrants II 275,000 — — — — 275,000 $ 0.20 December 2019 Warrants I 277,500 — — — — 277,500 $ 0.20 December 2019 Warrants II 277,500 — — — — 277,500 $ 0.20 1,286,233 72,249,968 (3 ) (33,262 ) (59,530 ) 73,443,406 During the years ended December 31, 2019 and 2018, the Company issued nil and 43,620 shares of its common stock, respectively, upon the cashless exercise of nil and 47,431 of its warrants, respectively. Warrants activities for the year ended December 31, 2019 are summarized as follows: Number of Weighted Weighted Aggregate Balance Outstanding December 31, 2017 204,203 $ 15.00 4.41 $ 5,754,600 Issued in connection with financings 102,222 $ 30.00 4.07 — Adjustment in connection with default provision 113,886 $ 3.75 2.09 — Reduction in warrants related to settlement of debt (33,262 ) $ 9.75 — — Exercised (47,430 ) $ 4.50 — — Balance Outstanding at December 31, 2018 339,619 $ 15.75 3.47 — Issued in connection with financings 1,165,002 0.44 4.90 — Increase in warrants related to default adjustment 71,938,788 0.05 3.85 — Expired (3 ) 225.00 — — Exercised — — — — Balance Outstanding at December 31, 2019 73,443,406 $ 0.09 3.83 $ — Exercisable at December 31, 2019 73,443,406 $ 0.09 3.83 $ — Stock options Effective February 18, 2011, our board of directors adopted and approved the 2011 stock option plan. The purpose of the 2011 stock option plan is to enhance the long-term stockholder value of our Company by offering opportunities to directors, key employees, officers, independent contractors and consultants of our Company to acquire and maintain stock ownership in our Company in order to give these persons the opportunity to participate in our Company’s growth and success, and to encourage them to remain in the service of our Company. A total of 57 options to acquire shares of our common stock were authorized under the 2011 stock option plan and during the 12 month period after the first anniversary of the adoption of the 2011 stock option plan, by our board of directors and during each 12 month period thereafter, our board of directors is authorized to increase the amount of options authorized under this plan by up to 14 shares. No options were granted under the 2011 stock option plan as of December 31, 2019. Stock-option issued during the year ended December 31, 2018 On May 8, 2018, the Company granted an aggregate of 23,334 stock options to purchase 23,334 shares of the Company’s common stock at $10.13 per share as follows: 20,000 options were granted to officers and directors of the Company, 667 options were granted to an employee, and 2,667 option to the Company’s scientific advisory board. These options vest in one year from the grant date and expire on May 8, 2028. The fair value of these option grants was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: dividend yield of 0%; expected volatility of 243%; risk-free interest rate of 2.81%; and, an estimated term based on the simplified method of 5.5 years. In connection with these options, the Company valued these options at a fair value of approximately $233,000 and will record stock-based compensation expense over the vesting term. Stock-option issued during the year ended December 31, 2019 On April 24, 2019 the board of directors of the Company granted an aggregate of 23,130 stock options, outside of the plan, to purchase shares of the Company’s common stock to Dr. Barnett and three non-employee members of the Board, Daniel S. Hoverman, Charles L. Rice and Neal Holcomb. Pursuant to Dr. Barnett’s employment agreement dated December 26, 2018, Dr. Barnett was granted 11,130 stock options with exercise price of $9.00 per share, vest dates of; (i) 3,710 on January 9, 2020; (ii) 3,710 on January 9, 2021; and (iii) 3,710 on January 9, 2022 and expire on April 24, 2030. The stock options vest so long as the optionee remains an employee of the Company on the vesting date (except as otherwise provided for in the employment agreement between the Company and the optionee). The fair value of this option grant was estimated on the date of grant using the Black-Scholes option-pricing model and the Company valued these options at a grant date fair value of $81,803 which will be expensed over the vesting period as stock-based compensation. On November 8, 2019, Dr. Barnett resigned as the Company’s Chief Executive Officer (see Note 12) which resulted in forfeiture of 11,130 of unvested stock options granted to him on December 26, 2018 (discussed above). The Company reversed $24,995 of stock-based compensation and $56,808 of the remaining deferred compensation which makes up the grant date fair value of $81,803 initially recorded as deferred compensation in April 2019. The three non-employee members of the Board were each granted 4,000 stock options for a total of 12,000 stock options with exercise price of $7.50 per share, vest date of April 24, 2020 and expires on April 24, 2030. The stock options vest so long as the optionee remains a member of the Board on the vesting date. The fair value of this option grant was estimated on the date of grant using the Black-Scholes option-pricing model and the Company valued these options at a grant date fair value of $88,200 which will be expensed over the vesting period as stock-based compensation During the years ended December 31, 2019 and 2018, the Company recorded stock-based compensation expense of $140,697 and $276,918 related to stock options, respectively. The Company uses the Black-Scholes pricing model to determine the fair value of its stock options which requires the Company to make several key judgments including: ● the value of the Company’s common stock; ● the expected life of issued stock options; ● the expected volatility of the Company’s stock price; ● the expected dividend yield to be realized over the life of the stock option; and ● the risk-free interest rate over the expected life of the stock options. The Company’s computation of the expected life of issued stock options was based on the simplified method as the Company does not have adequate exercise experience to determine the expected term. The interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. The computation of volatility was based on the historical volatility of the Company’s common stock. At December 31, 2019, there were 41,600 options issued and outstanding out of which 29,600 options were vested and exercisable. As of December 31, 2019, there was $35,280 of unvested stock-based compensation expense to be recognized through April 24, 2020. The aggregate intrinsic value at December 31, 2019 was $0 which was calculated based on the difference between the quoted share price on December 31, 2019 and the exercise price of the underlying options. Stock option activities for the year ended December 31, 2019 are summarized as follows: Number of Weighted Weighted Aggregate Balance Outstanding at December 31, 2018 29,600 $ 45.00 8.37 — Granted 23,130 $ 9.00 10.32 — Expired — $ — — — Forfeited (11,130 ) $ 9.00 — — Balance Outstanding at December 31, 2019 41,600 $ 36,69 9.34 $ — Exercisable at December 31, 2019 29,600 $ 47.91 8.37 $ —

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 10 – INCOME TAXES The Company maintains deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The deferred tax assets at December 31, 2019 and 2018 consist of net operating loss carryforwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of the attainment of future taxable income. The items accounting for the difference between income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2019 and 2018 were as follows: Years Ended December 31, 2019 2018 Income tax deduction (benefit) at U.S. statutory rate of 21% $ (1,974,471 ) $ 1,358,348 Income tax deduction (benefit) – state (752,180 ) 517,466 Non-deductible (income) expenses 2,254,568 (2,523,247 ) Change in valuation allowance 472,083 647,433 Total provision for income tax $ — $ — The Company’s approximate net deferred tax asset as of December 31, 2019 and 2018 was as follows: Years Ended December 31, 2019 2018 Net operating loss carryforward $ 2,605,720 $ 2,133,637 Total deferred tax asset 2,605,720 2,133,637 Less: valuation allowance (2,605,720 ) (2,133,637 ) Net deferred tax asset $ — $ — The gross operating loss carryforward was approximately $8,985,240 at December 31, 2019. The Company provided a valuation allowance equal to the net deferred income tax asset as of December 31, 2019 because it was not known whether future taxable income will be sufficient to utilize the loss carryforward. The increase in the valuation allowance was $472,083 in 2019. The potential tax benefit arising from the net operating loss carryforward of $1,486,204 from the period prior to Act’s effective date will expire in 2038. The potential tax benefit arising from the net operating loss carryforward of $1,119,516 from the period following to the Act’s effective date can be carried forward indefinitely within the annual usage limitations. Additionally, the future utilization of the net operating loss carryforward to offset future taxable income is subject to an annual limitation as a result of ownership or business changes that occurred in 2019 and may occur in the future. The Company has not conducted a study to determine the limitations on the utilization of these net operating loss carryforwards. If necessary, the deferred tax assets will be reduced by any carryforward that may not be utilized or expires prior to utilization as a result of such limitations, with a corresponding reduction of the valuation allowance. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2019, 2018 and 2017 Corporate Income Tax Returns are subject to Internal Revenue Service examination.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 11 – COMMITMENTS AND CONTINGENCIES Lease Effective September 1, 2015, the Company leases its facilities under a non-cancelable operating lease which expires on August 31, 2020. The Company has the right to renew certain facility leases for an additional five years. Rent expense is $3,200 base rent per month plus operating expense and other fees (see Note 5).

Employment Agreements

Employment Agreements	12 Months Ended
	Dec. 31, 2019
Employment Agreements
Employment Agreements	NOTE 12 – EMPLOYMENT AGREEMENTS On February 2, 2016, the Company entered into an employment agreement with Jonathan F. Head, Ph.D. (“Dr. Head”) to serve as the Company’s Chief Executive Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The employment agreement with Dr. Head provides that Dr. Head’s salary for calendar year 2016 shall be $275,000 and for calendar year 2017 and for each calendar year thereafter during the term of the employment agreement with Dr. Head shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Dr. Head for the immediately preceding calendar year. On February 2, 2016, the Company entered into an employment agreement with Andrew Kucharchuk (“Mr. Kucharchuk) to serve as the Company’s President and Chief Financial Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The employment agreement with Mr. Kucharchuk provides that Mr. Kucharchuk’s salary for calendar year 2016 shall be $200,000 and for calendar year 2017 and for each calendar year thereafter during the term of the employment agreement with Mr. Kucharchuk shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Mr. Kucharchuk for the immediately preceding calendar year. The above executives shall be eligible for an annual target bonus payment in an amount equal to ten percent of his base salary (“Bonus”). The Bonus is determined based on the achievement of certain performance objectives of the Company as established by the Board of Directors. The Bonus may be greater or less than the target Bonus, based on the level of achievement of the applicable performance objectives. Effective December 26, 2018, the Company replaced Dr. Jonathan Head and appointed Dr. Brian Barnett as the new Chief Executive Officer. Dr. Head will continue to serve the Company as the Chairman of the Board of Directors and now as its Chief Scientific Officer effective December 26, 2018. Dr. Head is still negotiating the terms of his new employment agreement for his new position as the Chief Scientific Officer, with the Company, as of the date of this report. On December 26, 2018, Dr. Barnett entered into an employment agreement with us (“Barnett Employment Agreement”) to serve as the Company’s Chief Executive Officer for a term of three years (from December 26, 2018 through December 26, 2021) that renews automatically for one-year periods unless a written notice of termination is provided not less than 180 days prior to the automatic renewal date. The Barnett Employment Agreement provides that Dr. Barnett’s salary for calendar year 2019 shall be $250,000 and for each calendar year thereafter during the term of the Barnett Employment Agreement shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Dr. Barnett for the immediately preceding calendar year. Dr. Barnett is also eligible to receive a performance-based bonus of up to $150,000 upon completion of specific metrics established by the Company’s Board of Directors and is entitled to participate in all medical and other benefits that the Company has established for its employees. Pursuant to the employment agreement, the Company will also grant options to purchase a number of shares of the Company’s common stock equal to $100,000 divided by the volume weighted average price of the Company’s common stock for the ten (10) business days prior to the effective date of the employment agreement. The option grant is subject to continued employment, and will vest ratably over the first three anniversary dates of the grant date. On April 24, 2019, Dr. Barnett was granted 11,130 stock options with exercise price of $9.00 per share, vest dates of; (i) 3,710 on January 9, 2020; (ii) 3,710 on January 9, 2021; and (iii) 3,710 on January 9, 2022 and expire on April 24, 2030. The stock options vest so long as the optionee remains an employee of the Company on the vesting date (except as otherwise provided for in the employment agreement between the Company and the optionee) (see Note 9). Additionally, upon the closing of a transaction during calendar year 2019 which results in the sale of common stock of the Company on terms acceptable to the Board that provides net proceeds to the Company of no less than $4,000,000 (a “Qualifying Transaction”), Dr. Barnett shall be granted options to purchase a number of shares of the Company’s common stock equal to $50,000 divided by the transaction price of the Company’s common stock in the Qualifying Transaction. The option grant is subject to continued employment, and will vest ratably over the first three anniversary dates of the date of the closing of the Qualifying Transaction. On November 8, 2019, Dr. Barnett resigned as the Company’s Chief Executive Officer (see Note 9) which resulted in forfeiture of 11,130 of unvested stock options granted to him on December 26, 2018 (discussed above). The Company reversed $24,995 of stock-based compensation and $56,808 of the remaining deferred compensation which makes up the grant date fair value of $81,803 initially recorded as deferred compensation in April 2019.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 - SUBSEQUENT EVENTS On January 27, 2020, the Company entered into a securities purchase agreement (the “Twenty-sixth Purchase Agreement”) for the sale of the Company’s convertible note and warrants. Pursuant to the Twenty- sixth Purchase Agreement, the Company issued to the Twenty- sixth Round Purchaser a note (the “January 2020 Note I”) with a principal amount of $55,000 with 10% OID and five-year warrants (the “January 2020 Warrants I”) to purchase an aggregate of 275,000 shares of the Company’s common stock at an exercise price of $0.20 per share (subject to adjustments under certain conditions as defined in the January 2020 Warrants I). The Company received $50,000 in aggregate net proceeds from the sale, net of $5,000 original issue discount. The January 2020 Note I bears an interest rate of 5% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in the January 2020 Note I)), shall mature on October 30, 2020 and the principal and interest are convertible at any time at a conversion price equal to $0.20 per share (subject to adjustment as provided in the January 2020 Note I); provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the January 2020 Note I shall be convertible and the January 2020 Warrants I shall be exercisable at 60% of the lowest closing price, as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the “Default Conversion Price”). The purchaser may not convert the January 2020 Note I to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 9.9% of the Company’s issued and outstanding common stock. The January 2020 Note I may be prepaid at any time until the 180th following the original issue date at an amount equal to (i) 115% of outstanding principal balance of the January 2020 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the January 2020 Note I and accrued and unpaid interest during month six following the original issue date. In order to prepay the January 2020 Note I, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the January 2020 Note I in whole or in part at the conversion price. The initial exercise price of the January 2020 Warrants I is $0.20 per share, subject to adjustment as described below, and are exercisable for five years after the issuance date. The January 2020 Warrants I is exercisable for cash at any time and are exercisable on a cashless basis at any time there is no effective registration statement registering the shares of common stock underlying the warrants. The exercise price of the warrants is subject to adjustment in the event of default, certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to the Company’s stockholders. Pursuant to the default provision, the January 2020 Warrants I shall be exercisable at the Default Conversion Price as defined above. The exercise price of the warrants is also subject to full ratchet price adjustment if the Company issues common stock at a price per share lower than the then-current exercise price of the warrants in the two years after the issue date of the Warrants (“Dilutive Issuances”). On January 29, 2020, the Company entered into a securities purchase agreement (the “Twenty-seventh Purchase Agreement”) for the sale of the Company’s convertible note and warrants. Pursuant to the Twenty-seventh Purchase Agreement, the Company issued to the Twenty- seventh Round Purchaser a note (the “January 2020 Note II”) with a principal amount of $55,000 with 10% OID and five-year warrants (the “January 2020 Warrants II”) to purchase an aggregate of 277,500 shares of the Company’s common stock at an exercise price of $0.20 per share (subject to adjustments under certain conditions as defined in the January 2020 Warrants II). The Company received $50,000 in aggregate net proceeds from the sale, net of $5,000 original issue discount. The January 2020 Note II bears an interest rate of 5% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in the January 2020 Note II)), shall mature on October 30, 2020 and the principal and interest are convertible at any time at a conversion price equal to $0.20 per share (subject to adjustment as provided in the January 2020 Note II); provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the January 2020 Note II shall be convertible and the January 2020 Warrants II shall be exercisable at 60% of the lowest closing price, as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the “Default Conversion Price”). The purchaser may not convert the January 2020 Note II to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 9.9% of the Company’s issued and outstanding common stock. The January 2020 Note II may be prepaid at any time until the 180th following the original issue date at an amount equal to (i) 115% of outstanding principal balance of the January 2020 Note II and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the January 2020 Note II and accrued and unpaid interest during month six following the original issue date. In order to prepay the January 2020 Note II, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the January 2020 Note II in whole or in part at the conversion price. The initial exercise price of the January 2020 Warrants II is $0.20 per share, subject to adjustment as described below, and are exercisable for five years after the issuance date. The January 2020 Warrants II is exercisable for cash at any time and are exercisable on a cashless basis at any time there is no effective registration statement registering the shares of common stock underlying the warrants. The exercise price of the Warrants is subject to adjustment in the event of default, certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to the Company’s stockholders. Pursuant to the default provision, the January 2020 Warrants II shall be exercisable at the Default Conversion Price as defined above. The exercise price of the warrants is also subject to full ratchet price adjustment if the Company issues common stock at a price per share lower than the then-current exercise price of the warrants in the two years after the issue date of the Warrants (“Dilutive Issuances”). On March 18, 2020, the Company entered into a securities purchase agreement (the “Twenty-Eight Purchase Agreement”) for the sale of the Company’s convertible note and warrants. Pursuant to the Twenty- Eight Purchase Agreement, the Company issued to the Twenty-Eight Round Purchaser a note (the “March 2020 Note I”) with a principal amount of $41,667 with 10% OID and five-year warrants (the “March 2020 Warrants I”) to purchase an aggregate of 208,333 shares of the Company’s common stock at an exercise price of $0.20 per share (subject to adjustments under certain conditions as defined in the March 2020 Warrants I). The Company received $37,500 in aggregate net proceeds from the sale, net of $4,167 original issue discount. The March 2020 Note I bears an interest rate of 5% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in the March 2020 Note I)), shall mature on November 18, 2020 and the principal and interest are convertible at any time at a conversion price equal to $0.20 per share (subject to adjustment as provided in the March 2020 Note I); provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the March 2020 Note I shall be convertible and the March 2020 Warrants I shall be exercisable at 60% of the lowest closing price, as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the “Default Conversion Price”). The purchaser may not convert the March 2020 Note I to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 9.9% of the Company’s issued and outstanding common stock. The March 2020 Note I may be prepaid at any time until the 180th following the original issue date at an amount equal to (i) 115% of outstanding principal balance of the March 2020 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the March 2020 Note I and accrued and unpaid interest during month six following the original issue date. In order to prepay the March 2020 Note I, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the March 2020 Note I in whole or in part at the conversion price. The initial exercise price of the March 2020 Warrants I is $0.20 per share, subject to adjustment as described below, and are exercisable for five years after the issuance date. The March 2020 Warrants I is exercisable for cash at any time and are exercisable on a cashless basis at any time there is no effective registration statement registering the shares of common stock underlying the warrants. The exercise price of the Warrants is subject to adjustment in the event of default, certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to the Company’s stockholders. Pursuant to the default provision, the March 2020 Warrants I shall be exercisable at the Default Conversion Price as defined above. The exercise price of the warrants is also subject to full ratchet price adjustment if the Company issues common stock at a price per share lower than the then-current exercise price of the warrants in the two years after the issue date of the Warrants (“Dilutive Issuances”). On March 18, 2020, the Company entered into a securities purchase agreement (the “Twenty-Ninth Purchase Agreement”) for the sale of the Company’s convertible note and warrants. Pursuant to the Twenty- Ninth Purchase Agreement, the Company issued to the Twenty-Ninth Round Purchaser a note (the “March 2020 Note II”) with a principal amount of $41,667 with 10% OID and five-year warrants (the “March 2020 Warrants II”) to purchase an aggregate of 208,333 shares of the Company’s common stock at an exercise price of $0.20 per share (subject to adjustments under certain conditions as defined in the March 2020 Warrants II). The Company received $37,500 in aggregate net proceeds from the sale, net of $4,167 original issue discount. The March 2020 Note II bears an interest rate of 5% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in the March 2020 Note II)), shall mature on November 18, 2020 and the principal and interest are convertible at any time at a conversion price equal to $0.20 per share (subject to adjustment as provided in the March 2020 Note II); provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the March 2020 Note II shall be convertible and the March 2020 Warrants II shall be exercisable at 60% of the lowest closing price, as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the “Default Conversion Price”). The purchaser may not convert the March 2020 Note II to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 9.9% of the Company’s issued and outstanding common stock. The March 2020 Note II may be prepaid at any time until the 180th following the original issue date at an amount equal to (i) 115% of outstanding principal balance of the March 2020 Note II and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the March 2020 Note II and accrued and unpaid interest during month six following the original issue date. In order to prepay the March 2020 Note II, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the March 2020 Note II in whole or in part at the conversion price. The initial exercise price of the March 2020 Warrants II is $0.20 per share, subject to adjustment as described below, and are exercisable for five years after the issuance date. The March 2020 Warrants II is exercisable for cash at any time and are exercisable on a cashless basis at any time there is no effective registration statement registering the shares of common stock underlying the warrants. The exercise price of the Warrants is subject to adjustment in the event of default, certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to the Company’s stockholders. Pursuant to the default provision, the March 2020 Warrants II shall be exercisable at the Default Conversion Price as defined above. The exercise price of the warrants is also subject to full ratchet price adjustment if the Company issues common stock at a price per share lower than the then-current exercise price of the warrants in the two years after the issue date of the Warrants (“Dilutive Issuances”). Subsequent to the year ended December 31, 2019, the lender converted $2,030 of principal and $107 of accrued interest into 41,903 shares of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of presentation and principals of consolidation The Company’s consolidated financial statements include the financial statements of OncBioMune Pharmaceuticals, Inc. and its wholly-owned subsidiaries, OncBioMune, Inc. for all periods presented. Vitel and Oncbiomune México, S.A. De C.V. (from March 10, 2017 to December 31, 2017) were treated as a discontinued operation through December 31, 2017 and were deconsolidated effective January 1, 2018 (see Note 3). All significant intercompany accounts and transactions have been eliminated in consolidation.
Going Concern	Going concern The consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying consolidated financial statements, the Company had net income (loss) of $(9,402,244) and $6,468,325 for the years ended December 31, 2019 and 2018, respectively, however the net income in 2018 resulted primarily from the change in fair value of derivative liabilities. The net loss from operations were $1,768,569 and $1,777,973 for the years ended December 31, 2019 and 2018, respectively. The net cash used in operations were $1,171,131 and $1,679,406 for the years ended December 31, 2019 and 2018, respectively. Additionally, the Company had an accumulated deficit of $26,589,908 and $17,187,664, at December 31, 2019 and 2018, respectively, had a stockholders’ deficit of $15,937,452 at December 31, 2019, had a working capital deficit of $15,969,504 at December 31, 2019. The Company had no revenues from continuing operations for the years ended December 31, 2019 and 2018, and we defaulted on our debt. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. Management cannot provide assurance that we will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that our capital resources are not currently adequate to continue operating and maintaining its business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and/or equity financings to fund its operations in the future and is seeking potential candidates for a merger or acquisition. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Use of Estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the years ended December 31, 2019 and 2018 include the valuation of liabilities of discontinued operations, useful life of property and equipment, valuation of operating lease right-of-use (“ROU”) assets and liabilities, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances, the fair value of non-cash equity transactions and the valuation of derivative liabilities.
Concentrations	Concentrations Generally, the Company relies on one vendor as a single source of raw materials to produce certain components of its cancer treatment products. Any production shortfall that impairs the supply of the antigen in ProscaVax™ to the Company could have a material adverse effect on the Company’s business, financial condition and results of operations. If the Company is unable to obtain a sufficient quantity of antigen, there could be a substantial delay in successfully developing a second source supplier.
Fair Value of Financial Instruments and Fair Value Measurements	Fair value of financial instruments and fair value measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on December 31, 2019. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, due from and to related parties, prepaid expenses, accounts payable and accrued liabilities approximate their fair market value based on the short-term maturity of these instruments. Assets or liabilities measured at fair value or a recurring basis included embedded conversion options in convertible debt and included warrants (see Note 6 and Note 9) and were as follows at December 31, 2019 and 2018: At December 31, 2019 At December 31, 2018 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative liabilities — — 9,320,052 — — 3,364,032 A roll forward of the level 3 valuation financial instruments is as follows: For the Year Ended December 31, 2019 2018 Balance at beginning of year $ 3,364,032 $ 11,966,760 Initial valuation of derivative liabilities included in debt discount 552,473 2,039,143 Initial valuation of derivative liabilities included in derivative income (expense) 22,546 1,811,617 Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon conversion of debt (357,355 ) (422,835 ) Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon cashless exercise of warrants — (666,756 ) Reclassification of derivative liabilities to gain (loss) on debt extinguishment for debt settlement — (1,323,111 ) Change in fair value included in derivative income (expense) 5,738,356 (10,040,786 ) Balance at end of year $ 9,320,052 $ 3,364,032 ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.
Cash and Cash Equivalents	Cash and cash equivalents For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At December 31, 2019 and 2018, the Company did not have any cash equivalents. The Company maintains its cash in bank and financial institution deposits that at times may exceed federally insured limits. There were no balances in excess of FDIC insured levels as of December 31, 2019 and 2018. The Company has not experienced any losses in such accounts through December 31, 2019.
Property and Equipment	Property and equipment Property are stated at cost and are depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.
Impairment of Long-lived Assets	Impairment of long-lived assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. For the years ended December 31, 2019 and 2018, the Company did not record any impairment loss.
Derivative Liabilities	Derivative liabilities The Company has certain financial instruments that are embedded derivatives associated with capital raises and certain warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10 – Derivative and Hedging – Contract in Entity’s Own Equity In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. These amendments simplify the accounting for certain financial instruments with down-round features. The amendments require companies to disregard the down-round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. The guidance was adopted as of January 1, 2019 and the Company elected to record the effect of this adoption retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the consolidated balance sheet as of the beginning of 2019, the period which the amendment is effective. The Company adopted ASU No. 2017-11 in the first quarter of 2019, and the adoption did not have any impact on its consolidated financial statement and there was no cumulative effect adjustment.
Revenue Recognition	Revenue recognition In May 2014, FASB issued an update Accounting Standards Update, ASU 2014-09, establishing ASC 606 - Revenue from Contracts with Customers. ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017, requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. The Company adopted this standard on January 1, 2018 using the modified retrospective approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Based on an evaluation of the impact ASU 2014-09 will have on the Company’s sources of revenue, the Company has concluded that ASU 2014-09 did not have any impact on the process for, timing of, and presentation and disclosure of revenue recognition from customers and there was no cumulative effect adjustment. The Company does not have revenues from continuing operations for the years ended December 31, 2019 and 2018.
Stock-based Compensation	Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Through March 31, 2018, pursuant to ASC 505-50 - Equity-Based Payments to Non-Employees, all share-based payments to non-employees, including grants of stock options, were recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black Scholes valuation model, the Company periodically reassessed the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and the Company adjusts the expense recognized in the consolidated financial statements accordingly. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions by expanding the scope of the stock-based compensation guidance in ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU No. 2018-07 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but entities may not adopt prior to adopting the new revenue recognition guidance in ASC 606. The Company early adopted ASU No. 2018-07 in the second quarter of 2018, and the adoption did not have any impact on its consolidated financial statements.
Income Taxes	Income taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes
Research and Development	Research and development Research and development costs incurred in the development of the Company’s products are expensed as incurred. For the years ended December 31, 2019 and 2018, research and development costs were $166,720 and $204,562, respectively, and are included in operating expenses on the accompanying consolidated statements of operations.
Basic and Diluted Loss Per Share	Basic and diluted loss per share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of December 31, 2019 and 2018 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: December 31, 2019 2018 Stock warrants 73.443.404 190,913 Convertible debt 59,751,203 — Stock options 41,600 29,600 Series A preferred stock 1,333 — Series B preferred stock 3,856 — 133,241,396 220,513 The following table presents a reconciliation of basic and diluted net loss per share: Years Ended December 31, 2019 2018 Income (loss) per common share — basic: Net income (loss) $ (9,402,244 ) $ 6,468,325 Weighted average common shares outstanding — basic 494,843 311,811 Net income (loss) per common share — basic: $ (19.00 ) $ 20.66 Income (loss) per common share — diluted: Income (loss) from continuing operations $ (9,402,244 ) $ 6,468,325 Add: interest on debt 1,795,398 2,130,838 Less: derivative income and debt settlement income 5,838,277 (10,343,503 ) Less: gain on foreign currency transactions — (33,633 ) Numerator for loss from continuing operations per common share — diluted (1,768,569 ) (1,777,973 ) Weighted average common shares outstanding — basic 494,843 311,811 Effect of dilutive securities: Preferred shares — 11,857 Warrants — 61,293 Convertible notes payable — 323,743 Weighted average common shares outstanding – diluted 494,843 708,704 Net loss per common share — diluted: $ (19.00 ) $ 9.09
Related Parties	Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On January 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating lease ROU assets represents the right to use the leased asset for the lease term
Recent Accounting Pronouncements	Recent accounting pronouncements In August 2018, the FASB issued ASU 2018-13 —Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement Removals 1. The amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy 2. The policy for timing of transfers between levels 3. The valuation processes for Level 3 fair value measurements 4. For nonpublic entities, the changes in unrealized gains and losses for the period included in earnings for recurring Level 3 fair value measurements held at the end of the reporting period. Modifications 1. In lieu of a roll forward for Level 3 fair value measurements, a nonpublic entity is required to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. 2. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. 3. The amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. Additions 1. The changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period. 2. The range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. In addition, the amendments eliminate at a minimum an entity shall disclose at a minimum Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Fair Value Based on Short - Term Maturity	The carrying amounts reported in the consolidated balance sheets for cash, due from and to related parties, prepaid expenses, accounts payable and accrued liabilities approximate their fair market value based on the short-term maturity of these instruments. At December 31, 2019 At December 31, 2018 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative liabilities — — 9,320,052 — — 3,364,032
Schedule of Roll Forward of Level 3 Valuation Financial Instruments	A roll forward of the level 3 valuation financial instruments is as follows: For the Year Ended December 31, 2019 2018 Balance at beginning of year $ 3,364,032 $ 11,966,760 Initial valuation of derivative liabilities included in debt discount 552,473 2,039,143 Initial valuation of derivative liabilities included in derivative income (expense) 22,546 1,811,617 Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon conversion of debt (357,355 ) (422,835 ) Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon cashless exercise of warrants — (666,756 ) Reclassification of derivative liabilities to gain (loss) on debt extinguishment for debt settlement — (1,323,111 ) Change in fair value included in derivative income (expense) 5,738,356 (10,040,786 ) Balance at end of year $ 9,320,052 $ 3,364,032
Schedule of Anti-dilutive Shares Outstanding	The following potentially dilutive equity securities outstanding as of December 31, 2019 and 2018 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: December 31, 2019 2018 Stock warrants 73.443.404 190,913 Convertible debt 59,751,203 — Stock options 41,600 29,600 Series A preferred stock 1,333 — Series B preferred stock 3,856 — 133,241,396 220,513
Schedule of Reconciliation of Basic and Diluted Net Loss Per Share	The following table presents a reconciliation of basic and diluted net loss per share: Years Ended December 31, 2019 2018 Income (loss) per common share — basic: Net income (loss) $ (9,402,244 ) $ 6,468,325 Weighted average common shares outstanding — basic 494,843 311,811 Net income (loss) per common share — basic: $ (19.00 ) $ 20.66 Income (loss) per common share — diluted: Income (loss) from continuing operations $ (9,402,244 ) $ 6,468,325 Add: interest on debt 1,795,398 2,130,838 Less: derivative income and debt settlement income 5,838,277 (10,343,503 ) Less: gain on foreign currency transactions — (33,633 ) Numerator for loss from continuing operations per common share — diluted (1,768,569 ) (1,777,973 ) Weighted average common shares outstanding — basic 494,843 311,811 Effect of dilutive securities: Preferred shares — 11,857 Warrants — 61,293 Convertible notes payable — 323,743 Weighted average common shares outstanding – diluted 494,843 708,704 Net loss per common share — diluted: $ (19.00 ) $ 9.09

Acquisition, Discontinuation _2

Acquisition, Discontinuation of Operations and Deconsolidation of Vitel and Oncbiomune Mexico (Tables)	12 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations Financial Statements	The assets and liabilities classified as discontinued operations in the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2019 and 2018 is set forth below. December 31, 2019 2018 Assets: Current assets: Cash $ — $ — Total current assets — — Total assets $ — $ — Liabilities: Current liabilities: Accounts payable $ 686,547 $ 692,592 Due to related parties — 432 Payroll liabilities — 1,972 Total current liabilities 686,547 694,996 Total liabilities $ 686,547 $ 694,996

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	At December 31, 2019 and 2018, property and equipment consisted of the following: Useful Life 2019 2018 Leasehold improvements 5 Years $ 10,976 $ 10,976 Furniture and equipment 5 Years 13,715 13,715 24,691 24,691 Less: accumulated depreciation (22,725 ) (20,387 ) Property and equipment, net $ 1,966 $ 4,304 For the years ended December 31, 2019 and 2018, depreciation and amortization expense amounted to $2,338 and $2,338, respectively.

Operating Lease Right-of-use _2

Operating Lease Right-of-use ('ROU') Assets and Operating Lease Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of Right-of-use Assets	Right-of-use asset (“ROU”) is summarized below: December 31, 2019 Operating office lease $ 59,216 Less accumulated reduction (35,530 ) Balance of ROU asset as of December 31, 2019 $ 23,686
Schedule of Operating Lease Liability	Operating lease liability related to the ROU asset is summarized below: December 31, 2019 Operating office lease $ 59,216 Total lease liabilities 59,216 Reduction of lease liability (35,530 ) Total as of December 31, 2019 23,686
Schedule of Operating Lease Payments Under Non-cancelable Lease	Future base lease payments under the non-cancelable operating lease at December 31, 2019 are as follows: Period ending Amount August 31, 2020 25,600 Total minimum non-cancelable operating lease payments 25,600 Less: discount to fair value (1,914 ) Total lease liability at December 31, 2019 $ 23,686

Convertible Debt (Tables)

Convertible Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Derivative Liabilities at Fair Value	During the years ended December 31, 2019 and 2018, the fair value of the derivative liabilities was estimated using the Binomial valuation model with the following assumptions: 2019 2018 Dividend rate — % — % Term (in years) 0.01 to 5.00 years 0.01 to 5.00 years Volatility 188.9 to 253.7 % 188.9 to 197.1 % Risk—free interest rate 1.59 to 2.96 % 2.07 to 2.96 %
Schedule of Convertible Debt	At December 31, 2019 and December 31, 2018, the convertible debt consisted of the following: December 31, 2019 2018 Principal amount $ 3,175,655 $ 2,436,394 Less: unamortized debt discount (260,358 ) (1,002,142 ) Convertible note payable, net $ 2,915,297 $ 1,434,252

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Schedule of Related Parties Activity	From time to time, the Company receives advances from and repays such advances to the Company’s former chief executive officer for working capital purposes and to repay indebtedness. For the years ended December 31, 2019 and 2017, due to related party activity consisted of the following: Total Balance due to related parties at December 31, 2017 $ (261,584 ) Working capital advances received (264,185 ) Repayments made 210,303 Balance due to related parties at December 31, 2018 $ (315,466 ) Working capital advances received (57,219 ) Repayments made — Balance due to related parties at December 31, 2019 $ (372,685 )

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Warrants Outstanding	Outstanding warrants as of December 31, 2019, all of which have been accounted for as derivative liabilities, are summarized as follows: Original Cumulative Anti-dilution Expired, Warrants Agreement Total Outstanding Exercise Warrants related to the 2016 subscription agreements 1,295 — (3 ) — — 1,292 $ 225.00 Warrants related to the 2017 subscription agreements 6,169 — — — — 6,169 $ 225.00 November 2016 Warrants 3,111 39,235 — — (12,099 ) 30,247 $ 4.50 June 2017 Warrants 2,074 58,423 — (8,067 ) (12,099 ) 40,331 $ 4.50 July 2017 Warrants 6,359 99,635 — — (35,332 ) 70,662 $ 4.50 January 2018 Warrants 11,111 4,356,265 — (10,078 ) — 4,357,298 $ 0.05 March 2018 Warrants 16,667 6,534,399 — (15,117 ) — 6,535,949 $ 0.05 September 2018 Warrants 68,056 39,964,625 — — — 40,032,681 $ 0.05 November 2018 Warrants 6,389 3,751,781 — — — 3,758,170 $ 0.05 March 2019 Warrants 2,778 1,631,209 — — — 1,633,987 $ 0.05 April 2019 Warrants I 1,389 815,605 — — — 816,994 $ 0.05 April 2019 Warrants II 10,264 6,027,318 — — — 6,037,582 $ 0.05 May 2019 Warrants 500 293,618 — — — 294,118 $ 0.05 June 2019 Warrants I 6,458 3,792,562 — — — 3,799,020 $ 0.05 June 2019 Warrants II 5,556 1,628,431 — — — 1,633,987 $ 0.05 July 2019 Warrants I 5,556 1,628,431 — — — 1,633,987 $ 0.05 July 2019 Warrants II 5,556 1,628,431 — — — 1,633,987 $ 0.05 August 2019 Warrants 2,778 — — — — 2,778 $ 15.00 September 2019 Warrants 16,667 — — — — 16,667 $ 15.00 November 2019 Warrants I 277,500 — — — — 277,500 $ 0.20 November 2019 Warrants II 275,000 — — — — 275,000 $ 0.20 December 2019 Warrants I 277,500 — — — — 277,500 $ 0.20 December 2019 Warrants II 277,500 — — — — 277,500 $ 0.20 1,286,233 72,249,968 (3 ) (33,262 ) (59,530 ) 73,443,406
Schedule of Warrant Activities	Warrants activities for the year ended December 31, 2019 are summarized as follows: Number of Weighted Weighted Aggregate Balance Outstanding December 31, 2017 204,203 $ 15.00 4.41 $ 5,754,600 Issued in connection with financings 102,222 $ 30.00 4.07 — Adjustment in connection with default provision 113,886 $ 3.75 2.09 — Reduction in warrants related to settlement of debt (33,262 ) $ 9.75 — — Exercised (47,430 ) $ 4.50 — — Balance Outstanding at December 31, 2018 339,619 $ 15.75 3.47 — Issued in connection with financings 1,165,002 0.44 4.90 — Increase in warrants related to default adjustment 71,938,788 0.05 3.85 — Expired (3 ) 225.00 — — Exercised — — — — Balance Outstanding at December 31, 2019 73,443,406 $ 0.09 3.83 $ — Exercisable at December 31, 2019 73,443,406 $ 0.09 3.83 $ —
Schedule of Stock Option Activities	Stock option activities for the year ended December 31, 2019 are summarized as follows: Number of Weighted Weighted Aggregate Balance Outstanding at December 31, 2018 29,600 $ 45.00 8.37 — Granted 23,130 $ 9.00 10.32 — Expired — $ — — — Forfeited (11,130 ) $ 9.00 — — Balance Outstanding at December 31, 2019 41,600 $ 36,69 9.34 $ — Exercisable at December 31, 2019 29,600 $ 47.91 8.37 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Effective Income Taxes and Reconciliation	The items accounting for the difference between income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2019 and 2018 were as follows: Years Ended December 31, 2019 2018 Income tax deduction (benefit) at U.S. statutory rate of 21% $ (1,974,471 ) $ 1,358,348 Income tax deduction (benefit) – state (752,180 ) 517,466 Non-deductible (income) expenses 2,254,568 (2,523,247 ) Change in valuation allowance 472,083 647,433 Total provision for income tax $ — $ —
Schedule of Deferred Tax Assets	The Company’s approximate net deferred tax asset as of December 31, 2019 and 2018 was as follows: Years Ended December 31, 2019 2018 Net operating loss carryforward $ 2,605,720 $ 2,133,637 Total deferred tax asset 2,605,720 2,133,637 Less: valuation allowance (2,605,720 ) (2,133,637 ) Net deferred tax asset $ — $ —

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative) - $ / shares	Aug. 28, 2019	Dec. 31, 2019	Aug. 06, 2019	Apr. 03, 2019	Feb. 20, 2019	Dec. 31, 2018	Mar. 10, 2017	Mar. 07, 2017	Aug. 20, 2015
Common stock, shares authorized		6,666,667	5,020,000,000	1,520,000,000		6,666,667
Common stock, par value		$ 0.0001				$ 0.0001
Preferred stock, shares authorized		26,667	20,000,000	20,000,000		26,667
Preferred stock, par value		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.075	$ 0.0001
Reverse stock split, description	Ratio of 1-for-750
Series A Preferred Stock [Member]
Preferred stock, shares authorized		1,333				1,333			26,667
Preferred stock, par value		$ 0.0001				$ 0.0001
Series B Preferred Stock [Member]
Preferred stock, shares authorized		10,523				10,523
Preferred stock, par value		$ 0.0001				$ 0.0001		$ 0.0001
Common Stock [Member]
Common stock, shares authorized			5,000,000,000	1,500,000,000
Common stock, par value			$ 0.0001	$ 0.0001
Minimum [Member]
Common stock, shares authorized			1,500,000,000	500,000,000
Maximum [Member]
Common stock, shares authorized			5,000,000,000	1,500,000,000
Vitel Stockholders [Member]
Acquisition percentage of issued and outstanding							100.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net income (loss)	$ (9,402,244)	$ 6,468,325
Loss from operations	(1,768,569)	(1,777,973)
Net cash used in operations	(1,171,131)	(1,679,406)
Accumulated deficit	(26,589,908)	(17,187,664)
Stockholders' deficit	(15,937,452)	(7,546,917)	$ (14,808,978)
Working capital deficit	15,969,504
Revenues
Cash equivalents
Cash FDIC
Impairment of long-lived assets
Revenue from continuing operations
Uncertain tax portion
Interest and penalties
Research and development costs	$ 166,720	$ 204,562
Minimum [Member]
Estimated useful lives	3 years
Maximum [Member]
Estimated useful lives	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Fair Value Based on Short - Term Maturity (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Derivative liabilities	$ 9,320,052	$ 3,364,032
Level 1 [Member]
Derivative liabilities
Level 2 [Member]
Derivative liabilities
Level 3 [Member]
Derivative liabilities	$ 9,320,052	$ 3,364,032

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Roll Forward of Level 3 Valuation Financial Instruments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Balance at beginning of year	$ 3,364,032	$ 11,966,760
Initial valuation of derivative liabilities included in debt discount	552,473	2,039,143
Initial valuation of derivative liabilities included in derivative income (expense)	22,546	1,811,617
Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon conversion of debt	(357,355)	(422,835)
Reclassification of derivative liabilities to gain (loss) on debt extinguishment upon cashless exercise of warrants		(666,756)
Reclassification of derivative liabilities to gain (loss) on debt extinguishment for debt settlement		(1,323,111)
Change in fair value included in derivative income (expense)	5,738,356	(10,040,786)
Balance at end of year	$ 9,320,052	$ 3,364,032

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Shares Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total antidilutive securities excluded from computation of earnings per share	133,241,396	220,513
Stock Warrants [Member]
Total antidilutive securities excluded from computation of earnings per share	73,443,404	190,913
Convertible Debt [Member]
Total antidilutive securities excluded from computation of earnings per share	59,751,203
Stock Options [Member]
Total antidilutive securities excluded from computation of earnings per share	41,600	29,600
Series A Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	1,333
Series B Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	3,856

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Net Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Net income (loss)	$ (9,402,244)	$ 6,468,325
Weighted average common shares outstanding - basic	494,843	311,811
Net income (loss) per common share - basic	$ (19)	$ 20.66
Income (loss) from continuing operations	$ (9,402,244)	$ 6,468,325
Add: interest on debt	1,795,398	2,130,838
Less: derivative income and debt settlement income	5,838,277	(10,343,503)
Less: gain on foreign currency transactions		(33,633)
Numerator for loss from continuing operations per common share - diluted	$ (1,768,569)	$ (1,777,973)
Effect of dilutive securities: Preferred shares		11,857
Effect of dilutive securities: Warrants		61,293
Effect of dilutive securities: Convertible notes payable		323,743
Weighted average common shares outstanding - diluted	494,843	708,704
Net loss per common share - diluted	$ (19)	$ 9.09

Acquisition, Discontinuation _3

Acquisition, Discontinuation of Operations and Deconsolidation of Vitel and Oncbiomune Mexico (Details Narrative) - USD ($)	1 Months Ended
	Dec. 31, 2017	Dec. 31, 2019	Feb. 20, 2019	Dec. 31, 2018
Preferred stock nominal value
Liabilities of discontinued operation		$ 686,547		$ 694,996
Vitel Stockholders [Member]
Liabilities of discontinued operation	$ 686,547
Series B Preferred Stock [Member]
Number of shares issued	6,667
Preferred stock, shares outstanding		3,856	6,667	10,523
Preferred stock nominal value			$ 500	$ 1
Share price, per share			$ 0.075
Common Stock [Member]
Number of shares issued	81,544

Acquisition, Discontinuation _4

Acquisition, Discontinuation of Operations and Deconsolidation of Vitel and Oncbiomune Mexico - Schedule of Discontinued Operations Financial Statements (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Cash
Total current assets
Total assets
Accounts payable	686,547	692,592
Due to related parties		432
Payroll liabilities		1,972
Total current liabilities	686,547	686,547
Total liabilities	$ 686,547	$ 694,996

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 2,338	$ 2,338

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Leasehold improvements	$ 10,976	$ 10,976
Furniture and equipment	13,715	13,715
Property and equipment, gross	24,691	24,691
Less: accumulated depreciation	(22,725)	(20,387)
Property and equipment, net	$ 1,966	$ 4,304
Leasehold Improvements [Member]
Useful life of assets	5 years
Furniture and Equipment [Member]
Useful life of assets	5 years

Operating Lease Right-of-use _3

Operating Lease Right-of-use ('ROU') Assets and Operating Lease Liabilities (Details Narrative) - USD ($)	Sep. 02, 2015	Sep. 30, 2015	Dec. 31, 2019	Jan. 02, 2019
Lease expiration	Aug. 31, 2020	Aug. 31, 2020
Monthly base rent			$ 3,200
Right-of-use assets and lease liabilities				$ 59,216
Lease cost			49,137
Base lease cost			38,400
Common area and other expenses			$ 10,737
Lease liability discount rate			10.00%
Beginning September 2015 [Member]
Monthly base rent			$ 3,067
Beginning September 2018 [Member]
Monthly base rent			$ 3,200

Operating Lease Right-of-use _4

Operating Lease Right-of-use ('ROU') Assets and Operating Lease Liabilities - Schedule of Right-of-use Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating office lease	$ 59,216
Less accumulated reduction	(35,530)
Right-of-use asset, net	$ 23,686

Operating Lease Right-of-use _5

Operating Lease Right-of-use ('ROU') Assets and Operating Lease Liabilities - Schedule of Operating Lease Liability (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating office lease	$ 59,216
Total lease liabilities	59,216
Reduction of lease liability	(35,530)
Right-of-use asset, net	$ 23,686

Schedule of Operating Lease Pay

Schedule of Operating Lease Payments Under Non-cancelable Lease (Details)	Dec. 31, 2019USD ($)
Total lease liability at December 31, 2019	$ 59,216
Lease Agreement [Member]
August 31, 2020	25,600
Total minimum non-cancelable operating lease payments	25,600
Less: discount to fair value	(1,914)
Total lease liability at December 31, 2019	$ 23,686

Convertible Debt (Details Narra

Convertible Debt (Details Narrative) - USD ($)

Dec. 23, 2019

Nov. 15, 2019

Sep. 27, 2019

Aug. 28, 2019

Aug. 19, 2019

Jul. 08, 2019

Jul. 02, 2019

Jun. 26, 2019

Jun. 03, 2019

May 29, 2019

Apr. 29, 2019

Apr. 02, 2019

Mar. 25, 2019

Jan. 18, 2019

Nov. 13, 2018

Oct. 16, 2018

Sep. 24, 2018

Jul. 25, 2018

Jun. 05, 2018

Mar. 13, 2018

Jan. 29, 2018

Jul. 26, 2017

Jun. 02, 2017

May 23, 2017

Nov. 23, 2016

Dec. 31, 2018

Sep. 30, 2017

May 31, 2017

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Oct. 31, 2014

Interest expense debt

$ 1,795,398

$ 2,130,838

Number of common stock issued for cashless exercise

12,729

Cashless exercise warrants, shares

12,099

Convertible debt

$ 2,436,394

3,175,655

2,436,394

Common stock issued conversion of convertible debt

871,512

Gain (Loss) on extinguishment of debt

(77,375)

2,114,335

Debt discount

$ 1,002,142

260,358

1,002,142

Derivative income (expense)

(5,760,902)

8,229,168

Amortization of debt discounts

$ 1,434,148

$ 1,465,057

June 2017 Warrants [Member]

Warrant to purchase common shares

2,074

Warrants exercise price per share

$ 4.50

Number of warrants outstanding

40,331

Number of common stock issued for cashless exercise

11,332

Cashless exercise warrants, shares

12,099

July 2017 Warrants [Member]

Warrant to purchase common shares

6,359

Warrants exercise price per share

$ 4.50

Common stock upon conversion of debt, shares

32,289

Number of warrants outstanding

70,662

Cashless exercise warrants, shares

35,332

March 2018 Warrants [Member]

Warrant to purchase common shares

16,667

Warrants exercise price per share

$ 0.05

Number of warrants outstanding

6,535,949

September 2018 Warrants [Member]

Warrant to purchase common shares

68,056

Warrants exercise price per share

$ 0.05

Number of warrants outstanding

40,032,681

September 2018 Warrants [Member] | Seventh Month Amortization [Member]

Warrants exercise price per share

$ 30

Common stock upon conversion of debt, shares

39,934

Number of warrants outstanding

68,056

40,032,680

Number of warrants increased

39,964,624

November 2018 Warrants [Member]

Warrant to purchase common shares

6,389

Warrants exercise price per share

$ 0.05

Number of warrants outstanding

3,758,170

May 2019 Warrants [Member]

Warrant to purchase common shares

500

Warrants exercise price per share

$ 0.05

Number of warrants outstanding

294,118

June 2019 Warrants I [Member]

Warrant to purchase common shares

6,458

Warrants exercise price per share

$ 0.05

Number of warrants outstanding

3,799,020

Maximum [Member] | September 2018 Warrants [Member] | Seventh Month Amortization [Member]

Number of warrants outstanding

40,032,680

Maximum [Member] | November 2018 Warrants [Member] | Seventh Month Amortization [Member]

Number of warrants outstanding

3,758,170

December 2019 Notes and related Warrants [Member]

Derivative income (expense)

$ 22,546

Securities Purchase Agreement [Member] | June 2017 Warrants [Member]

Warrants exercise price per share

$ 4.50

Debt conversion price

$ 4.50

Sale of stock, description of transaction

Subsequent to the date of these June 2017 Notes, the Company sold stock at a share price of $37.50 per share and then $7.50 per share. Accordingly, pursuant to these ratchet provisions, the conversion price of the notes were lowered to $4.50 per shares and the exercise price of the June 2017 Warrants were lowered to $4.50 per share and the total number of June 2017 Warrants were increased on a full ratchet basis from 2,074 warrants to 60,497 warrants, an increase of 58,423 warrants

Sale of stock price per share

$ 37.50

Number of warrants outstanding

2,074

Number of warrants increased

58,423

Securities Purchase Agreement [Member] | Maximum [Member] | June 2017 Warrants [Member]

Number of warrants outstanding

60,497

November 2016 Warrants [Member]

Number of warrants outstanding

30,247

2nd Securities Purchase Agreement [Member] | June 2017 Warrants [Member]

Warrant to purchase common shares

2,074

Warrants exercise price per share

$ 131.25

Puritan Settlement Agreement [Member]

Warrant to purchase common shares

33,262

Accrued interest

$ 654,191

Aggregate purchase price

900,000

Payment for issuance of securities

$ 245,809

Gain (Loss) on extinguishment of debt

$ 1,323,111

Puritan Settlement Agreement [Member] | June 2017 Warrants [Member]

Warrant to purchase common shares

8,066

Third Securities Purchase Agreements [Member] | July 2017 Warrants [Member]

Warrants exercise price per share

$ 4.50

Debt conversion price

$ 4.50

Sale of stock, description of transaction

Subsequent to the date of these July 2017 Notes, the Company sold stock at a share price of $37.50 per share and then at $7.50 per share. Accordingly, pursuant to these ratchet provisions, the conversion price of the July 2017 Notes was lowered to $4.50 per share and the exercise price of the July 2017 Warrants was lowered to $4.50 per share and the total number of July 2017 Warrants was increased on a full ratchet basis from 6,359 warrants to 105,994 warrants, an increase of 99,635 warrants

Sale of stock price per share

$ 37.50

Number of warrants outstanding

6,359

Number of warrants increased

99,635

Third Securities Purchase Agreements [Member] | Maximum [Member] | July 2017 Warrants [Member]

Number of warrants outstanding

105,994

Fourth Securities Purchase Agreement [Member] | January 2018 Warrants [Member]

Warrant to purchase common shares

10,078

Number of warrants outstanding

4,357,298

Fourth Securities Purchase Agreement [Member] | Maximum [Member] | January 2018 Warrants [Member]

Number of warrants outstanding

4,367,376

Fifth Securities Purchase Agreement [Member] | March 2018 Warrants [Member]

Number of warrants outstanding

15,117

16,667

6,535,948

Number of warrants increased

6,534,399

Fifth Securities Purchase Agreement [Member] | Maximum [Member] | March 2018 Warrants [Member]

Number of warrants outstanding

6,551,066

Eighth Securities Purchase Agreement [Member] | November 2018 Warrants [Member]

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Number of warrants outstanding

6,389

3,758,170

Number of warrants increased

3,751,781

Eleventh Securities Purchase Agreement [Member] | March 2019 Warrants [Member]

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Number of warrants outstanding

2,778

1,633,987

Number of warrants increased

1,631,209

Eleventh Securities Purchase Agreement [Member] | Maximum [Member] | March 2019 Warrants [Member]

Number of warrants outstanding

1,633,987

Twelfth Securities Purchase Agreement [Member] | April 2019 Warrant I [Member]

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Number of warrants outstanding

1,389

816,994

Number of warrants increased

815,605

Twelfth Securities Purchase Agreement [Member] | Maximum [Member] | April 2019 Warrant I [Member]

Number of warrants outstanding

816,994

Thirteenth Securities Purchase Agreement [Member] | April 2019 Warrants II [Member]

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Number of warrants outstanding

10,264

6,037,582

Number of warrants increased

6,027,318

Thirteenth Securities Purchase Agreement [Member] | Maximum [Member] | April 2019 Warrants II [Member]

Number of warrants outstanding

6,037,582

Fourteenth Securities Purchase Agreement [Member] | May 2019 Warrants [Member]

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Number of warrants outstanding

500

294,118

Number of warrants increased

293,618

Fourteenth Securities Purchase Agreement [Member] | Maximum [Member] | May 2019 Warrants [Member]

Number of warrants outstanding

294,118

Fifteenth Securities Purchase Agreement [Member] | June 2019 Warrants I [Member]

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Number of warrants outstanding

6,458

3,799,020

Number of warrants increased

3,792,562

Fifteenth Securities Purchase Agreement [Member] | June 2019 Warrant II [Member]

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Number of warrants outstanding

5,556

1,633,987

Number of warrants increased

1,628,431

Fifteenth Securities Purchase Agreement [Member] | Maximum [Member] | June 2019 Warrant II [Member]

Number of warrants outstanding

1,633,987

Twenty-First Purchase Agreement [Member]

Debt face amount

$ 436,281

Common stock upon conversion of debt, shares

508,999

Common stock issued conversion of convertible debt

$ 871,512

Gain (Loss) on extinguishment of debt

434,731

Twenty-First Purchase Agreement [Member] | Default Interest [Member]

Common stock upon conversion of debt

36,134

Twenty-First Purchase Agreement [Member] | Accrued Interest [Member]

Common stock upon conversion of debt

44,308

Twenty-First Purchase Agreement [Member] | Principal [Member]

Common stock upon conversion of debt

356,339

Derivative Liabilities Pursuant to Notes and Warrants [Member]

Embedded derivative liability

575,019

Debt discount

552,473

Derivative income (expense)

(5,760,902)

$ 8,229,168

Amortization of debt discounts

$ 1,434,148

$ 1,465,057

Termination Agreements [Member]

Debt maturity date

Oct. 20, 2015

Common stock, value

$ 10,100,000

November 2016 Notes [Member]

Warrants exercise price per share

$ 4.50

$ 4.50

Common stock upon conversion of debt, shares

17,372

11,150

Sale of stock, description of transaction

Subsequent to the date of these November 2016 Notes, the Company sold stock at a share price of $56.25 per share then $37.50 per share and then $7.50 per share. Accordingly, pursuant to these ratchet provisions, the conversion price on the November 2016 Notes were lowered to $37.50 per share then to $22.50 per share and then to $4.50 per share and the exercise price of the November 2016 Warrants was lowered to $4.50.

Sale of stock price per share

$ 56.25

$ 56.25

Number of warrants outstanding

3,111

3,111

Number of warrants increased

39,235

39,235

November 2016 Notes [Member] | Minimum [Member]

Number of warrants outstanding

42,346

42,346

November 2016 Notes [Member] | Outstanding Principal [Member]

Common stock upon conversion of debt

$ 139,712

$ 369,423

November 2016 Notes [Member] | Interest [Member]

Common stock upon conversion of debt

$ 21,869

32,878

November 2016 Notes [Member] | Securities Purchase Agreement [Member]

Aggregate subscription amount

$ 350,000

Debt instrument description

(i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes (the "November 2016 Notes") and (ii) warrants (the "Warrants") to purchase aggregate of 3,111 shares of the Company's common stock at an initial exercise price of $131.25 (subject to adjustments under certain conditions as defined in the Warrants) (see below for reduction of warrant exercise price) which are exercisable for a period of five years from November 23, 2016.

Percentage of original debt discount

14.29%

Warrant to purchase common shares

3,111

Warrants exercise price per share

$ 131.25

Warrant exercisable term

5 years

Debt face amount

$ 350,000

Proceeds from issuance of debt

300,000

Debt original issue discount

$ 50,000

Debt bore interest

10.00%

Increase in debt instrument, interest rate

24.00%

Debt maturity date

Jul. 23, 2017

Debt conversion price

$ 112.50

Conversion price, percentage

60.00%

November 2016 Notes [Member] | Forbearance Agreement [Member]

Debt bore interest

24.00%

Aggregate amount owing under the notes

$ 509,135

Debt instrument default amount

$ 141,299

Reduced accrued interest payable

$ 17,836

Debt settlement expense

141,299

Increased principal balance

$ 159,135

Interest expense debt

$ 42,327

November 2016 Warrants [Member]

Conversion price, percentage

60.00%

June 2017 Notes [Member]

Common stock upon conversion of debt, shares

19,819

June 2017 Notes [Member] | Six Month Amortization [Member]

Amortization debt percentage

120.00%

June 2017 Notes [Member] | Seven or Eight Month Amortization [Member]

Amortization debt percentage

125.00%

June 2017 Notes [Member] | Outstanding Principal [Member]

Common stock upon conversion of debt

$ 118,786

June 2017 Notes [Member] | Interest [Member]

Common stock upon conversion of debt

$ 7,036

June 2017 Notes [Member] | 2nd Securities Purchase Agreement [Member]

Aggregate subscription amount

$ 233,345

Debt instrument description

(i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes (the "June 2017 Notes"); and (ii) warrants (the "June 2017 Warrants") to purchase an aggregate of 2,074 shares of the Company's common stock at an initial exercise price of $131.25 (subject to adjustments under certain conditions as defined in the June 2017 Warrants) and exercisable for five years after the issuance date.

Percentage of original debt discount

14.29%

Warrant exercisable term

5 years

Debt face amount

$ 233,345

Proceeds from issuance of debt

190,000

Debt original issue discount

$ 33,345

Debt bore interest

10.00%

Increase in debt instrument, interest rate

24.00%

Debt maturity date

Feb. 2, 2018

Debt conversion price

$ 112.50

Conversion price, percentage

60.00%

Interest expense debt

$ 2,268

Common stock upon conversion of debt, shares

32,180

Offering costs

$ 10,000

Convertible debt conversion description

(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the June 2017 Notes and accrued and unpaid interest during months four through six following the Original Issue Date. In order to prepay the June 2017 Notes, the Company shall provide 20 Trading Days prior written notice to the Holder, during which time the Holder may convert the June 2017 Notes in whole or in part at the Conversion Price.

June 2017 Notes [Member] | 2nd Securities Purchase Agreement [Member] | Outstanding Principal [Member]

Debt face amount

$ 1,495

Common stock upon conversion of debt

$ 37,814

77,782

June 2017 Notes [Member] | 2nd Securities Purchase Agreement [Member] | Interest [Member]

Common stock upon conversion of debt

4,534

13,593

June 2017 Notes [Member] | 2nd Securities Purchase Agreement [Member] | Default Interest [Member]

Common stock upon conversion of debt

36,134

June 2017 Notes [Member] | 2nd Securities Purchase Agreement [Member] | Accrued Interest [Member]

Debt face amount

0

Accrued interest

0

July 2017 Notes [Member]

Debt face amount

28,655

Accrued interest

32,372

July 2017 Notes [Member] | Six Month Amortization [Member]

Amortization debt percentage

110.00%

July 2017 Notes [Member] | Seven or Eight Month Amortization [Member]

Amortization debt percentage

115.00%

July 2017 Notes [Member] | Third Securities Purchase Agreements [Member]

Aggregate subscription amount

$ 300,000

Debt instrument description

(i) 10% Original Issue Discount 5% Senior Secured Convertible Notes in the aggregate principal amount of $333,883 (the "July 2017 Notes"); and (ii) warrants (the "July 2017 Warrants") to purchase an aggregate of 6,359 shares of the Company's common stock at an exercise price of $75.00 per share (subject to adjustments under certain conditions as defined in the Warrants).

Percentage of original debt discount

10.00%

Warrant to purchase common shares

6,359

Warrants exercise price per share

$ 75

Debt face amount

$ 333,883

Debt bore interest

5.00%

Increase in debt instrument, interest rate

24.00%

Debt maturity date

Mar. 25, 2018

Debt conversion price

$ 52.50

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the July 2017 Notes and accrued and unpaid interest during months four through seven following the Original Issue Date. In order to prepay the July 2017 Notes, the Company shall provide 20 Trading Days prior written notice to the Purchaser, during which time the Purchaser may convert the July 2017 Notes in whole or in part at the Conversion Price.

July 2017 Notes [Member] | Third Securities Purchase Agreement [Member]

Debt face amount

155,812

Common stock upon conversion of debt, shares

31,053

Accrued interest

38,395

July 2017 Notes [Member] | Third Securities Purchase Agreement [Member] | Outstanding Principal [Member]

Common stock upon conversion of debt

$ 111,295

July 2017 Notes [Member] | Third Securities Purchase Agreement [Member] | Default Interest [Member]

Common stock upon conversion of debt

47,028

July 2017 Notes [Member] | Third Securities Purchase Agreement [Member] | Accrued Interest [Member]

Common stock upon conversion of debt

11,414

First Assigned Note [Member] | Assignment Agreement [Member]

Debt face amount

$ 111,295

Accrued interest

29,180

Default interest amount

53,733

Convertible debt

$ 194,208

Second Assigned Note [Member]

Debt face amount

$ 32,384

Accrued interest

30,612

Default interest amount

53,733

Prepayment premium amount

49,535

Aggregate penalty amount

$ 103,268

Second Assigned Note [Member] | Assignment Agreement [Member]

Debt face amount

$ 194,208

174,264

Common stock upon conversion of debt

$ 65,140

$ 17,500

Common stock upon conversion of debt, shares

106,622

4,818

Accrued interest

3,204

$ 0

Convertible debt

246,765

Prepayment premium amount

$ 49,535

Aggregate penalty amount

103,268

January 2018 Notes [Member] | Fourth Securities Purchase Agreement [Member]

Aggregate subscription amount

$ 333,333

Debt instrument description

(i) 10% Original Issue Discount 5% Senior Secured Convertible Notes in the aggregate principal amount of $333,333 (the "January 2018 Notes"); and (ii) 5 year warrants (the "January 2018 Warrants") to purchase an aggregate of 11,111 shares of the Company's common stock at an exercise price of $30.00 per share (subject to adjustments under certain conditions as defined in the Warrants).

Percentage of original debt discount

10.00%

Warrant to purchase common shares

11,111

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

111,111

$ 333,333

213,277

Proceeds from issuance of debt

295,000

Debt original issue discount

$ 33,333

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Sep. 29, 2018

Debt conversion price

$ 22.50

Conversion price, percentage

60.00%

Common stock upon conversion of debt

$ 8,945

Common stock upon conversion of debt, shares

47,119

Offering costs

$ 5,000

Convertible debt conversion description

(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the five months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the January 2018 Notes and accrued and unpaid interest during the six month following the Original Issue Date. In order to prepay the January 2018 Notes, the Company shall provide 20 Trading Days prior written notice to the Purchaser, during which time the Purchaser may convert the January 2018 Notes in whole or in part at the Conversion Price.

Accrued interest

98,031

$ 67,185

January 2018 Notes [Member] | Fourth Securities Purchase Agreement [Member] | Six Month Amortization [Member]

Amortization debt percentage

110.00%

January 2018 Notes [Member] | Fourth Securities Purchase Agreement [Member] | Seven or Eight Month Amortization [Member]

Amortization debt percentage

115.00%

January 2018 Warrants [Member] | Fourth Securities Purchase Agreement [Member]

Number of warrants outstanding

11,111

Number of warrants increased

4,356,265

March 2018 Notes [Member] | Fifth Securities Purchase Agreement [Member]

Aggregate subscription amount

$ 333,333

Debt instrument description

(i) 10% Original Issue Discount 5% Senior Secured Convertible Notes in the aggregate principal amount of $333,333 (the "March 2018 Notes") and (ii) warrants (the "March 2018 Warrants") to purchase an aggregate of 16,667 shares of the Company's common stock at an exercise price of $30.00 per share.

Percentage of original debt discount

10.00%

Warrant to purchase common shares

16,667

Warrants exercise price per share

$ 30

Debt face amount

111,111

$ 333,333

152,778

Proceeds from issuance of debt

61,000

Debt original issue discount

$ 33,333

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Nov. 13, 2018

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Offering costs

$ 10,000

Convertible debt conversion description

(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest through the five month anniversary of the issue date, and (ii) 120% of outstanding principal balance of the Notes and accrued and unpaid interest from the fifth month anniversary of the issue date through the six month anniversary of the issue date. In order to prepay the March 2018 Notes, the Company shall provide 20 trading days prior written notice to the holders, during which time a holder may convert its March 2018 Notes in whole or in part at the conversion price.

Accrued interest

$ 97,383

$ 46,463

Payment of legal and accounting fees

$ 29,000

Escrow account balance

$ 200,000

March 2018 Notes [Member] | Fifth Securities Purchase Agreement [Member] | Six Month Amortization [Member]

Amortization debt percentage

110.00%

March 2018 Notes [Member] | Fifth Securities Purchase Agreement [Member] | Seven or Eight Month Amortization [Member]

Amortization debt percentage

115.00%

March 2017 Notes [Member] | Fifth Securities Purchase Agreement [Member]

Common stock upon conversion of debt, shares

21,779

March 2017 Notes [Member] | Fifth Securities Purchase Agreement [Member] | Outstanding Principal [Member]

Common stock upon conversion of debt

$ 69,444

March 2017 Notes [Member] | Fifth Securities Purchase Agreement [Member] | Interest [Member]

Common stock upon conversion of debt

$ 612

July 2018 Note [Member] | Seventh Month Amortization [Member]

Amortization debt percentage

110.00%

July 2018 Note [Member] | Original Issuance Date [Member]

Amortization debt percentage

125.00%

July 2018 Note [Member] | Sixth Securities Purchase Agreement [Member]

Debt instrument description

The July 2018 Note may be prepaid at the Company's option at a 105% premium between 30 days and 180 days after issuance, and at a 110% premium between 180 days after issuance and the maturity date. Upon certain events defined in the note as "sale events", the holder may demand repayment of the note for 125% of the principal plus accrued but unpaid interest. The note also includes certain penalties upon the occurrence of an event of default, including an increase in the principal and reduction in the conversion rate, as further described in the July 2018 Note.

Percentage of original debt discount

25.00%

24.00%

Debt face amount

$ 150,000

$ 150,000

Debt bore interest

8.00%

Debt maturity date

Jul. 24, 2019

Amortization debt percentage

105.00%

Accrued interest

26,342

Beneficial ownership exceed the issued outstanding common stock, percentage

4.99%

September 2018 Note [Member] | Seventh Month Amortization [Member]

Amortization debt percentage

115.00%

September 2018 Note [Member] | Seventh Securities Purchase Agreement [Member]

Aggregate subscription amount

$ 1,361,111

Debt instrument description

(i) 10% Original Issue Discount 5% Senior Convertible Notes in the aggregate principal amount of $1,361,111 (the "September 2018 Notes") and (ii) 5 year warrants (the "September 2018 Warrants") to purchase an aggregate of 68,056 shares of the Company's common stock at an exercise price of $30.00 per share (subject to adjustments under certain conditions as defined in the September 2018 Warrants).

Percentage of original debt discount

10.00%

Warrant to purchase common shares

68,056

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

$ 1,361,111

1,303,038

Proceeds from issuance of debt

1,181,643

Debt original issue discount

$ 136,111

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

May 24, 2019

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the note and accrued and unpaid interest through the five month anniversary of the issue date, and (ii) 120% of outstanding principal balance of the notes and accrued and unpaid interest during month six following the original issuance date of the notes. In order to prepay the notes, the Company shall provide 20 trading days prior written notice to the holders, during which time a holder may convert its note in whole or in part at the conversion price.

Amortization debt percentage

110.00%

Accrued interest

149,283

Legal fees

$ 43,357

September 2018 Warrants [Member] | Outstanding Principal [Member] | Seventh Month Amortization [Member]

Common stock upon conversion of debt

58,073

September 2018 Warrants [Member] | Interest [Member] | Seventh Month Amortization [Member]

Common stock upon conversion of debt

28,234

November 2018 Note [Member] | Eighth Month Amortization [Member]

Amortization debt percentage

115.00%

November 2018 Note [Member] | Eighth Securities Purchase Agreement [Member]

Aggregate subscription amount

$ 127,778

Debt instrument description

(i) 10% Original Issue Discount 5% Senior Convertible Note in the aggregate principal amount of $127,778 (the "November 2018 Note") and (ii) 5 year warrants (the "November 2018 Warrants") to purchase an aggregate of 6,389 shares of the Company's common stock at an exercise price of $30.00 per share (subject to adjustments under certain conditions as defined in the November 2018 Warrants).

Percentage of original debt discount

10.00%

Warrant to purchase common shares

6,389

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

$ 127,778

127,778

Proceeds from issuance of debt

112,500

Debt original issue discount

$ 12,778

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Jul. 13, 2019

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest through the five month anniversary of the issue date, and (ii) 120% of outstanding principal balance of the Note and accrued and unpaid interest during month six following the original issuance date of the notes. In order to prepay the notes, the Company shall provide 20 trading days prior written notice to the holders, during which time a holder may convert its note in whole or in part at the conversion price.

Amortization debt percentage

110.00%

Accrued interest

$ 17,287

Legal fees

$ 2,500

January 2019 Note I [Member] | Ninth Securities Purchase Agreement [Member]

Common stock upon conversion of debt, shares

256,262

January 2019 Note I [Member] | Ninth Securities Purchase Agreement [Member] | Institutional Investor [Member]

Debt face amount

$ 146,875

$ 84,920

Proceeds from issuance of debt

125,000

Debt original issue discount

$ 12,500

Debt bore interest

5.00%

Debt maturity date

Jan. 18, 2020

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Accrued interest

8,257

Payment of legal and accounting fees

$ 9,375

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

Cash redemption premium, percentage

115.00%

Note prepayment description

The Company prepays the January 2019 Note I within 150 days of its issuance, the Company must pay the principal at a cash redemption premium of 115%, in addition to accrued interest; if such prepayment is made from the151st day to the 180th day after issuance, then such redemption premium is 120%, in addition to accrued interest. After the 180th day following the issuance of the January 2019 Note I, there shall be no further right of prepayment.

January 2019 Note I [Member] | Ninth Securities Purchase Agreement [Member] | Outstanding Principal [Member]

Common stock upon conversion of debt

61,955

January 2019 Note I [Member] | Ninth Securities Purchase Agreement [Member] | Accrued Interest [Member]

Common stock upon conversion of debt

1,852

January 2019 Note I [Member] | Tenth Securities Purchase Agreement [Member] | Outstanding Principal [Member] | Institutional Investor [Member]

Common stock upon conversion of debt

15,000

January 2019 Note I [Member] | Tenth Securities Purchase Agreement [Member] | Accrued Interest [Member] | Institutional Investor [Member]

Common stock upon conversion of debt

16

January 2019 Note II [Member] | Tenth Securities Purchase Agreement [Member] | Institutional Investor [Member]

Debt face amount

$ 88,125

$ 73,125

Proceeds from issuance of debt

75,000

Debt original issue discount

$ 7,500

Debt bore interest

5.00%

Debt maturity date

Jan. 18, 2020

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Common stock upon conversion of debt, shares

3,708

Accrued interest

$ 10,445

Payment of legal and accounting fees

$ 5,625

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

Cash redemption premium, percentage

115.00%

Note prepayment description

The Company prepays the January 2019 Note II within 150 days of its issuance, the Company must pay the principal at a cash redemption premium of 115%, in addition to accrued interest; if such prepayment is made from the151st day to the 180th day after issuance, then such redemption premium is 120%, in addition to accrued interest. After the 180th day following the issuance of the January 2019 Note II, there shall be no further right of prepayment.

March 2019 Note [Member] | Eleventh Securities Purchase Agreement [Member]

Aggregate subscription amount

$ 50,000

Debt instrument description

(i) 10% Original Issue Discount and 5% Senior Convertible Notes in the aggregate principal amount of $55,556 (the "March 2019 Note") and (ii) 5 year warrants (the "March 2019 Warrants") to purchase an aggregate of 2,778 shares of the Company's common stock at an exercise price of $30.00 per share (subject to adjustments under certain conditions as defined in the March 2019 Warrants).

Percentage of original debt discount

10.00%

Warrant to purchase common shares

2,778

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

$ 55,556

55,556

Proceeds from issuance of debt

50,000

Debt original issue discount

$ 5,556

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Nov. 25, 2019

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the March 2019 Note and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the March 2019 Note and accrued and unpaid interest during month six following the original issue date.

Accrued interest

6,512

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

April 2019 Note I [Member] | Twelfth Securities Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

1,389

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

$ 27,778

27,778

Proceeds from issuance of debt

25,000

Debt original issue discount

$ 2,778

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Dec. 2, 2019

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the April 2019 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the April 2019 Note I and accrued and unpaid interest during month six following the original issue date.

Accrued interest

3,225

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

April 2019 Note II [Member] | Thirteenth Securities Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

10,264

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

$ 205,279

205,279

Proceeds from issuance of debt

185,450

Debt original issue discount

$ 19,829

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Dec. 29, 2019

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the April 2019 Notes II and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the April 2019 Notes II and accrued and unpaid interest during month six following the original issue date.

Accrued interest

23,076

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

May 2019 Note [Member] | Fourteenth Securities Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

500

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

$ 10,000

10,000

Proceeds from issuance of debt

9,000

Debt original issue discount

$ 1,000

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Jan. 29, 2020

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the May 2019 Notes and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the May 2019 Notes and accrued and unpaid interest during month six following the original issue date.

Accrued interest

905

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

June 2019 Notes I [Member] | Fifteenth Securities Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

6,458

Warrants exercise price per share

$ 30

Warrant exercisable term

5 years

Debt face amount

$ 129,167

129,167

Proceeds from issuance of debt

116,250

Debt original issue discount

$ 12,917

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Feb. 3, 2020

Debt conversion price

$ 15

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the June 2019 Notes I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the June 2019 Notes I and accrued and unpaid interest during month six following the original issue date.

Accrued interest

$ 11,600

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

June 2019 Notes I [Member] | Fifteenth Securities Purchase Agreement [Member] | Maximum [Member]

Number of warrants outstanding

3,799,020

June 2019 Notes II [Member] | Fifteenth Securities Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

5,556

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Debt face amount

$ 55,556

$ 55,556

Proceeds from issuance of debt

50,000

Debt original issue discount

$ 5,556

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Feb. 26, 2020

Debt conversion price

$ 7.50

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the June 2019 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the June 2019 Note II and accrued and unpaid interest during month six following the original issue date.

Accrued interest

4,815

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

July 2019 Note I [Member] | Seventh Securities Purchase Agreements [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

5,556

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Debt face amount

$ 55,556

55,556

Proceeds from issuance of debt

50,000

Debt original issue discount

$ 5,556

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Feb. 26, 2020

Debt conversion price

$ 7.50

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the July 2019 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the July 2019 Note I and accrued and unpaid interest during month six following the original issue date.

Accrued interest

$ 4,769

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

July 2019 Warrants I [Member] | Seventh Securities Purchase Agreements [Member]

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Number of warrants outstanding

5,556

1,633,987

Number of warrants increased

1,628,431

July 2019 Warrants I [Member] | Seventh Securities Purchase Agreements [Member] | Maximum [Member]

Number of warrants outstanding

1,633,987

July 2019 Note II [Member] | Eighth Securities Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

5,556

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Debt face amount

$ 55,556

$ 55,556

Proceeds from issuance of debt

50,000

Debt original issue discount

$ 5,556

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Feb. 26, 2020

Debt conversion price

$ 7.50

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the July 2019 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the July 2019 Note II and accrued and unpaid interest during month six following the original issue date. In order to prepay the July 2019 Note II, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the July 2019 Note II in whole or in part at the conversion price.

Accrued interest

$ 4,723

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

July 2019 Warrants II [Member] | Eighth Securities Purchase Agreement [Member]

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Number of warrants outstanding

5,556

1,633,987

Number of warrants increased

1,628,431

July 2019 Warrants II [Member] | Eighth Securities Purchase Agreement [Member] | Maximum [Member]

Number of warrants outstanding

1,633,987

August 2019 Note I [Member] | Nineteenth Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

2,778

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Debt face amount

$ 27,778

$ 27,778

Proceeds from issuance of debt

25,000

Debt original issue discount

$ 2,778

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Mar. 30, 2020

Debt conversion price

$ 7.50

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the August 2019 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the August 2019 Note I and accrued and unpaid interest during month six following the original issue date. In order to prepay the August 2019 Note I, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the August 2019 Note I in whole or in part at the conversion price.

Accrued interest

$ 510

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

August 2019 Warrants I [Member] | Nineteenth Purchase Agreement [Member]

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Number of warrants outstanding

2,778

August 2019 Note II [Member] | Twentieth Purchase Agreement [Member] | Institutional Investor [Member]

Debt face amount

$ 29,700

$ 29,700

Proceeds from issuance of debt

$ 25,000

Debt bore interest

5.00%

Debt maturity date

Aug. 27, 2020

Debt conversion price

$ 7.50

Conversion price, percentage

60.00%

Accrued interest

509

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

Note prepayment description

The August 2019 Note II can be prepaid during the first 180 days for a redemption price equal to 140% of the sum of the outstanding principal and accrued interest and shall forfeit the right of prepayment after the 180th day following the issuance date.

Original debt discount and legal fees

$ 4,700

September 2019 Note [Member] | Twenty-First Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

16,667

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Debt face amount

$ 166,667

166,667

Proceeds from issuance of debt

150,000

Debt original issue discount

$ 16,667

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

May 27, 2020

Debt conversion price

$ 7.50

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance and accrued and unpaid interest during month six following the original issue date. The Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the September 2019 Note in whole or in part at the conversion price.

Accrued interest

$ 2,100

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

September 2019 Note [Member] | Twenty-First Purchase Agreement [Member] | Note Purchasers [Member]

Convertible debt conversion description

The Note Purchasers will not have the right to convert any portion of the Notes if the Note Purchaser, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to its conversion. The Note Purchaser may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company.

September 2019 Warrants [Member] | Twenty-First Purchase Agreement [Member]

Warrants exercise price per share

$ 15

Warrant exercisable term

5 years

Number of warrants outstanding

16,667

Beneficial ownership exceed the issued outstanding common stock, percentage

50.00%

September 2019 Warrants [Member] | Twenty-First Purchase Agreement [Member] | Warrants Holder [Member]

Beneficial ownership exceed the issued outstanding common stock, percentage

9.99%

November 2019 Note [Member] | Twenty-Second Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

277,500

Warrants exercise price per share

$ 0.20

Warrant exercisable term

5 years

Debt face amount

$ 55,500

$ 55,500

Proceeds from issuance of debt

50,000

Debt original issue discount

$ 5,500

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Aug. 30, 2020

Debt conversion price

$ 0.20

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the November 2019 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the November 2019 Note I and accrued and unpaid interest during month six following the original issue date. In order to prepay the November 2019 Note I, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the November 2019 Note I in whole or in part at the conversion price.

Accrued interest

350

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

November 2019 Note [Member] | Twenty-Third Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

277,500

Warrants exercise price per share

$ 0.20

Warrant exercisable term

5 years

Debt face amount

$ 55,500

55,500

Proceeds from issuance of debt

50,000

Debt original issue discount

$ 5,500

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Aug. 30, 2020

Debt conversion price

$ 0.20

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the November 2019 Note II and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the November 2019 Note II and accrued and unpaid interest during month six following the original issue date. In order to prepay the November 2019 Note II, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the November 2019 Note II in whole or in part at the conversion price.

Accrued interest

$ 350

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

November 2019 Warrants [Member] | Twenty-Second Purchase Agreement [Member]

Warrants exercise price per share

$ 0.20

Warrant exercisable term

5 years

Number of warrants outstanding

277,500

November 2019 Warrants [Member] | Twenty-Third Purchase Agreement [Member]

Warrants exercise price per share

$ 0.20

Warrant exercisable term

5 years

Number of warrants outstanding

277,500

December 2019 Note [Member] | Twenty-Fourth Purchase Agreement [Member]

Percentage of original debt discount

10.00%

Warrant to purchase common shares

277,500

Warrants exercise price per share

$ 0.20

Warrant exercisable term

5 years

Debt face amount

$ 55,500

$ 55,500

Proceeds from issuance of debt

50,000

Debt original issue discount

$ 5,500

Debt bore interest

5.00%

Increase in debt instrument, interest rate

18.00%

Debt maturity date

Sep. 30, 2020

Debt conversion price

$ 0.20

Conversion price, percentage

60.00%

Convertible debt conversion description

(i) 115% of outstanding principal balance of the December 2019 Note I and accrued and unpaid interest during the period from the original issue date through the five months following the original issue date, and (ii) 120% of the outstanding principal balance of the December 2019 Note I and accrued and unpaid interest during month six following the original issue date. In order to prepay the December 2019 Note I, the Company shall provide twenty trading days prior written notice to the lender, during which time the purchaser may convert the December 2019 Note I in whole or in part at the conversion price.

Accrued interest

$ 61

Beneficial ownership exceed the issued outstanding common stock, percentage

9.90%

December 2019 Warrants [Member] | Twenty-Fourth Purchase Agreement [Member]

Warrants exercise price per share

$ 0.20

Warrant exercisable term

5 years

Number of warrants outstanding

277,500

Promissory Note [Member]

Revolving line of credit

$ 100,000

Convertible Debt - Schedule of

Convertible Debt - Schedule of Derivative Liabilities at Fair Value (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Dividend Rate [Member]
Fair value assumptions, measurement input, percentage	0	0
Term (in years) [Member] | Minimum [Member]
Fair value assumptions, measurement input, term	4 days	4 days
Term (in years) [Member] | Maximum [Member]
Fair value assumptions, measurement input, term	5 years	5 years
Volatility [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	188.9	188.9
Volatility [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	253.7	197.1
Risk-Free Interest Rate [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	1.59	2.07
Risk-Free Interest Rate [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	2.96	2.96

Convertible Debt - Schedule o_2

Convertible Debt - Schedule of Convertible Debt (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Principal amount	$ 3,175,655	$ 2,436,394
Less: unamortized debt discount	(260,358)	(1,002,142)
Convertible note payable, net	$ 2,915,297	$ 1,434,252

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - Loan Agreement [Member] - USD ($)	4 Months Ended
	Sep. 30, 2017	Dec. 31, 2019	Dec. 31, 2018
Proceeds from borrowed loans	$ 538,875
Debt instrument, interest rate	33.30%
Loan principal due to third parties		$ 538,875	$ 538,875
Interest payable		$ 430,223	$ 250,777

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Parties Activity (Details) - Former Chief Executive Officer [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance due to related parties, beginning balance	$ (315,466)	$ (261,584)
Working capital advances received	(57,219)	(264,185)
Repayments made		210,303
Balance due to related parties, ending balance	$ (372,685)	$ (315,466)

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details Narrative) - USD ($)	Jan. 09, 2022	Jan. 09, 2021	Jan. 09, 2020	Nov. 08, 2019	Aug. 28, 2019	Apr. 24, 2019	Feb. 20, 2019	May 08, 2018	Mar. 07, 2017	Aug. 20, 2015	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Aug. 06, 2019	Apr. 03, 2019	Dec. 31, 2016	Feb. 18, 2011
Common stock, shares authorized														6,666,667	6,666,667	5,020,000,000	1,520,000,000
Common stock, par value														$ 0.0001	$ 0.0001
Preferred stock, shares authorized														26,667	26,667	20,000,000	20,000,000
Preferred stock, par value							$ 0.075							$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Reverse stock split, description					Ratio of 1-for-750
Number of shares redeem							6,667
Value of shares repurchased							$ 500
Aggregate fair value of conversion														$ 1,135,700	$ 2,034,143
Loss on debt extinguishment														$ (77,375)	2,114,335
Cashless exercise warrants, shares												12,099
Number of stock option shares granted														23,130
Stock options exercise price per share														$ 9
Stock-based compensation expense														$ 140,697	329,418
Stock Option [Member]
Number of stock option shares granted								23,334
Number of stock option to purchase shares of common stock								23,334
Stock option purchase price per share								$ 10.13
Stock option expire term								1 year
Stock option expiration date								May 8, 2028
Dividend yield								0.00%
Expected volatility								243.00%
Risk-free interest rate								2.81%
Estimated term								5 years 6 months
Fair value of stock option vested														233,000
Stock-based compensation expense														$ 140,697	$ 276,918
Number of stock options issued and outstanding														41,600
Stock option vested and exercisable														29,600
Unvested stock based compensation expenses														$ 35,280
Aggregate intrinsic value														$ 0
2011 Stock Option Plan [Member]
Number of option authorized to purchase common stock																			57
Unit Subscription Agreement [Member]
Number of shares issued during period															800
Number of shares issued during period															$ 6,000
Share price per share															$ 7.50
Agreement [Member]
Number of shares issued during period															3,333
Number of shares issued during period															$ 52,500
Share price per share															$ 15.75
Board of Directors [Member] | Stock Option [Member]
Number of stock option shares granted						23,130
Officers and Directors [Member] | Stock Option [Member]
Number of stock option shares granted								20,000
Employee [Member] | Stock Option [Member]
Number of stock option shares granted								667
Scientific Advisory Board [Member] | Stock Option [Member]
Number of stock option shares granted								2,667
Dr. Barnett [Member] | Stock Option [Member]
Number of stock option shares granted						11,130
Stock option expiration date						Apr. 24, 2030
Fair value of stock option vested				$ 81,803		$ 81,803
Stock options exercise price per share						$ 9
Forfeiture shares				11,130
Stock-based compensation expense				$ 24,995
Remaining deferred compensation				$ 56,808
Dr. Barnett [Member] | Stock Option [Member] | Scenario, Plan [Member]
Number of stock option shares granted	3,710	3,710	3,710
Non-Employee One [Member] | Stock Option [Member]
Number of stock option shares granted														4,000
Non-Employee Two [Member] | Stock Option [Member]
Number of stock option shares granted														4,000
Non-Employee Three [Member] | Stock Option [Member]
Number of stock option shares granted														4,000
Three Non-Employees [Member] | Stock Option [Member]
Number of stock option shares granted														12,000
Stock option expiration date														Apr. 24, 2030
Fair value of stock option vested														$ 88,200
Stock options exercise price per share														$ 7.50
Vesting date														Apr. 24, 2020
Series A Preferred Stock [Member]
Preferred stock, shares authorized										26,667				1,333	1,333
Preferred stock, par value														$ 0.0001	$ 0.0001
Preferred stock designated										1,333
Stockholder voting rights										Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.
Preferred stock, shares issued														1,333	1,333
Preferred stock, shares outstanding														1,333	1,333
Series A Preferred Stock [Member] | Articles of Incorporation Amendment to Implement Reverse Stock Split [Member]
Common stock, shares authorized					1,333
Series A Preferred Stock [Member] | CEO [Member]
Preferred stock, shares issued														667
Preferred stock, shares outstanding														667
Series A Preferred Stock [Member] | Board of Directors [Member]
Preferred stock, shares issued														666
Preferred stock, shares outstanding														666
Series B Preferred Stock [Member]
Preferred stock, shares authorized														10,523	10,523
Preferred stock, par value									$ 0.0001					$ 0.0001	$ 0.0001
Preferred stock designated									10,523
Stockholder voting rights									Each share of Series B preferred stock entitles the holder to 100 votes on all matters submitted to a vote of the Company's stockholders.
Preferred stock, shares issued														3,856	10,523
Preferred stock, shares outstanding							6,667							3,856	10,523
Common stock outstanding, percentage									5.00%
Number of shares issued during period											6,667
Series B Preferred Stock [Member] | Articles of Incorporation Amendment to Implement Reverse Stock Split [Member]
Common stock, shares authorized					10,523
Series B Preferred Stock [Member] | Jonathan [Member]
Number of shares issued during period													3,856
Series B Preferred Stock [Member] | Banco Actinver [Member]
Common stock outstanding, percentage													100.00%
Number of shares issued during period													6,667
Common Stock [Member]
Common stock, shares authorized																5,000,000,000	1,500,000,000
Common stock, par value																$ 0.0001	$ 0.0001
Number of shares issued during period											81,544
Common stock issued upon the conversion of debt, shares														508,999	78,175
Common stock issued upon the conversion of debt														$ 356,339	$ 387,292
Conversion of debt accrued interest														44,308	40,320
Conversion of debt default interest														36,134	$ 55,890
Aggregate fair value of conversion														871,512
Debt face amount														436,281
Loss on debt extinguishment														$ 434,731
Common Stock [Member] | Articles of Incorporation Amendment to Implement Reverse Stock Split [Member]
Common stock, shares authorized					6,666,667
Preferred Stock [Member] | Articles of Incorporation Amendment to Implement Reverse Stock Split [Member]
Common stock, shares authorized					26,667
Warrants [Member]
Number of shares issued during period															43,620
Cashless exercise warrants, shares															47,431
Warrant to purchase common shares														1,286,233
Warrants outstanding														73,443,406
Warrants [Member] | Subscription Agreements [Member]
Warrant to purchase common shares											6,169							1,295
Warrant term											5 years							5 years
Warrants exercise price per share											$ 225							$ 225
Warrants issued														1,292	1,292
Warrants outstanding														1,292	1,292
Warrants One [Member] | Subscription Agreements [Member]
Warrants issued														6,169	6,169
Warrants outstanding														6,169	6,169
Minimum [Member]
Common stock, shares authorized																1,500,000,000	500,000,000
Minimum [Member] | Warrants [Member]
Warrants exercise price per share														$ 131
Maximum [Member]
Common stock, shares authorized																5,000,000,000	1,500,000,000
Maximum [Member] | Board of Directors [Member] | 2011 Stock Option Plan [Member]
Number of option authorized to purchase common stock																			14
Maximum [Member] | Warrants [Member]
Warrants exercise price per share														$ 0.20

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) - Schedule of Warrants Outstanding (Details)	Dec. 31, 2019$ / sharesshares
Warrants Related to the 2016 Subscription Agreements [Member]
Original warrants issued	1,295
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited	(3)
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	1,292
Exercise price | $ / shares	$ 225
Warrants Related to the 2017 Subscription Agreements [Member]
Original warrants issued	6,169
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	6,169
Exercise price | $ / shares	$ 225
November 2016 Warrants [Member]
Original warrants issued	3,111
Cumulative Anti-dilution adjustment	39,235
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)	(12,099)
Outstanding warrants	30,247
Exercise price | $ / shares	$ 4.50
June 2017 Warrants [Member]
Original warrants issued	2,074
Cumulative Anti-dilution adjustment	58,423
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)	(8,067)
Total warrants exercised (Cashless exercise)	(12,099)
Outstanding warrants	40,331
Exercise price | $ / shares	$ 4.50
July 2017 Warrants [Member]
Original warrants issued	6,359
Cumulative Anti-dilution adjustment	99,635
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)	(35,332)
Outstanding warrants	70,662
Exercise price | $ / shares	$ 4.50
January 2018 Warrants [Member]
Original warrants issued	11,111
Cumulative Anti-dilution adjustment	4,356,265
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)	(10,078)
Total warrants exercised (Cashless exercise)
Outstanding warrants	4,357,298
Exercise price | $ / shares	$ 0.05
March 2018 Warrants [Member]
Original warrants issued	16,667
Cumulative Anti-dilution adjustment	6,534,399
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)	(15,117)
Total warrants exercised (Cashless exercise)
Outstanding warrants	6,535,949
Exercise price | $ / shares	$ 0.05
September 2018 Warrants [Member]
Original warrants issued	68,056
Cumulative Anti-dilution adjustment	39,964,625
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	40,032,681
Exercise price | $ / shares	$ 0.05
November 2018 Warrants [Member]
Original warrants issued	6,389
Cumulative Anti-dilution adjustment	3,751,781
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	3,758,170
Exercise price | $ / shares	$ 0.05
March 2019 Warrant [Member]
Original warrants issued	2,778
Cumulative Anti-dilution adjustment	1,631,209
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	1,633,987
Exercise price | $ / shares	$ 0.05
April 2019 Warrants I [Member]
Original warrants issued	1,389
Cumulative Anti-dilution adjustment	815,605
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	816,994
Exercise price | $ / shares	$ 0.05
April 2019 Warrants II [Member]
Original warrants issued	10,264
Cumulative Anti-dilution adjustment	6,027,318
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	6,037,582
Exercise price | $ / shares	$ 0.05
May 2019 Warrants [Member]
Original warrants issued	500
Cumulative Anti-dilution adjustment	293,618
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	294,118
Exercise price | $ / shares	$ 0.05
June 2019 Warrants I [Member]
Original warrants issued	6,458
Cumulative Anti-dilution adjustment	3,792,562
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	3,799,020
Exercise price | $ / shares	$ 0.05
June 2019 Warrants II [Member]
Original warrants issued	5,556
Cumulative Anti-dilution adjustment	1,628,431
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	1,633,987
Exercise price | $ / shares	$ 0.05
July 2019 Warrants I [Member]
Original warrants issued	5,556
Cumulative Anti-dilution adjustment	1,628,431
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	1,633,987
Exercise price | $ / shares	$ 0.05
July 2019 Warrants II [Member]
Original warrants issued	5,556
Cumulative Anti-dilution adjustment	1,628,431
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	1,633,987
Exercise price | $ / shares	$ 0.05
August 2019 Warrants [Member]
Original warrants issued	2,778
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	2,778
Exercise price | $ / shares	$ 15
September 2019 Warrants [Member]
Original warrants issued	16,667
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	16,667
Exercise price | $ / shares	$ 15
November 2019 Warrants I [Member]
Original warrants issued	277,500
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	277,500
Exercise price | $ / shares	$ 0.20
November 2019 Warrants II [Member]
Original warrants issued	275,000
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	275,000
Exercise price | $ / shares	$ 0.20
December 2019 Warrants I [Member]
Original warrants issued	277,500
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	277,500
Exercise price | $ / shares	$ 0.20
December 2019 Warrants II [Member]
Original warrants issued	277,500
Cumulative Anti-dilution adjustment
Expired, Cancelled or Forfeited
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)
Total warrants exercised (Cashless exercise)
Outstanding warrants	277,500
Exercise price | $ / shares	$ 0.20
Warrants [Member]
Original warrants issued	1,286,233
Cumulative Anti-dilution adjustment	72,249,968
Expired, Cancelled or Forfeited	(3)
Warrants purchased back - Puritan Settlement Agreement (post anti-dilution)	(33,262)
Total warrants exercised (Cashless exercise)	(59,530)
Outstanding warrants	73,443,406

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) - Schedule of Warrant Activities (Details) - Stock Warrants [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Warrants, Outstanding Beginning balance	339,619	204,203
Number of Warrants, Issued in connection with financings	1,165,002	102,222
Number of Warrants, Adjustment in connection with default provision		113,886
Number of Warrants, Reduction in warrants related to settlement of debt		(33,262)
Number of Warrants, Exercised		(47,430)
Number of Warrants, Increase in warrants related to default adjustment	71,938,788
Number of Warrants, Expired	(3)
Number of Warrants, Outstanding Ending balance	73,443,406	339,619
Number of Warrants, Exercisable	73,443,406
Weighted Average Exercise Price, Outstanding Beginning balance	$ 15.75	$ 15
Weighted Average Exercise Price, Issued in connection with financings	0.44	30
Weighted Average Exercise Price, Adjustment in connection with default provision		3.75
Weighted Average Exercise Price, Reduction in warrants related to settlement of debt		9.75
Weighted Average Exercise Price, Exercised		4.50
Weighted Average Exercise Price, Increase in warrants related to default adjustment	0.05
Weighted Average Exercise Price, Expired	225
Weighted Average Exercise Price, Outstanding Ending balance	0.09	$ 15.75
Weighted Average Exercise Price, Exercisable	$ 0.09
Weighted Average Remaining Contractual Term (Years), Beginning Balance Outstanding	3 years 5 months 20 days	4 years 4 months 28 days
Weighted Average Remaining Contractual Term (Years), Issued in connection with financings	4 years 10 months 25 days	4 years 26 days
Weighted Average Remaining Contractual Term (Years), Adjustment in connection with default provision		2 years 1 month 2 days
Weighted Average Remaining Contractual Term (Years), Increase in warrants related to default adjustment	3 years 10 months 6 days
Weighted Average Remaining Contractual Term (Years), Ending Balance Outstanding	3 years 9 months 29 days	3 years 5 months 20 days
Weighted Average Remaining Contractual Term (Years), Exercisable	3 years 9 months 29 days
Aggregate Intrinsic Value, Beginning Balance Outstanding		$ 5,754,600
Aggregate Intrinsic Value, Ending Balance Outstanding
Aggregate Intrinsic Value, Exercisable

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) - Schedule of Stock Option Activities (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Equity [Abstract]
Number of Option Outstanding, Beginning Balance | shares	29,600
Number of Option, Granted | shares	23,130
Number of Option, Expired | shares
Number of Option, Forfeited | shares	(11,130)
Number of Option Outstanding, Ending Balance | shares	41,600
Number of Option Exercisable, Ending Balance | shares	29,600
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 45
Weighted Average Exercise Price Granted | $ / shares	9
Weighted Average Exercise Price Expired | $ / shares
Weighted Average Exercise Price Forfeited | $ / shares	9
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	36.69
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 47.91
Weighted Average Remaining Contractual Term (Years) Outstanding, Beginning Balance	8 years 4 months 13 days
Weighted Average Remaining Contractual Term (Years) Outstanding, Granted	10 years 3 months 26 days
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	9 years 4 months 2 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	8 years 4 months 13 days
Aggregate Intrinsic Value Balance Outstanding, Ending Balance | $
Aggregate Intrinsic Value Exercisable, Ending Balance | $

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2019USD ($)
Net operating loss carryforward	$ 8,985,240
Increase in valuation allowance	$ 472,083
Loss carryforward expiration year	expire in 2038
Prior to Act's Effective Date [Member]
Net operating loss carryforward	$ 1,486,204
After Act's Effective Date [Member]
Net operating loss carryforward	$ 1,119,516

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Taxes and Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income tax deduction (benefit) at U.S. statutory rate of 21%	$ (1,974,471)	$ 1,358,348
Income tax deduction (benefit) - state	(752,180)	517,466
Non-deductible (income) expenses	2,254,568	(2,523,247)
Change in valuation allowance	472,083	647,433
Total provision for income tax

Income Taxes - Schedule of Ef_2

Income Taxes - Schedule of Effective Income Taxes and Reconciliation (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Percentage of statutory rate	21.00%	21.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 2,605,720	$ 2,133,637
Total deferred tax asset	2,605,720	2,133,637
Less: Valuation allowance	(2,605,720)	(2,133,637)
Net deferred tax asset

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Sep. 02, 2015	Sep. 30, 2015	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Lease expiration	Aug. 31, 2020	Aug. 31, 2020
Rent expense			$ 3,200

Employment Agreements (Details

Employment Agreements (Details Narrative) - USD ($)	Jan. 09, 2022	Jan. 09, 2021	Jan. 09, 2020	Nov. 08, 2019	Apr. 24, 2019	Dec. 26, 2018	May 08, 2018	Feb. 02, 2016	Dec. 31, 2019	Dec. 31, 2018
Number of stock option shares granted									23,130
Stock option exercise price									$ 9
Proceeds from sale of common stock										$ 6,000
Stock-based compensation expense									140,697	329,418
Stock Option [Member]
Number of stock option shares granted							23,334
Stock option expiration date							May 8, 2028
Stock-based compensation expense									140,697	$ 276,918
Fair value of stock option vested									$ 233,000
Barnett Employment Agreement [Member]
Salaries						$ 250,000
Bonus amount						150,000
Value of options granted to purchase common stock						100,000
Proceeds from sale of common stock						4,000,000
Jonathan F. Head, Ph.D [Member] | Employment Agreement [Member]
Salaries								$ 275,000
Andrew Kucharchuk Chief Financial Officer [Member] | Employment Agreement [Member]
Salaries								$ 200,000
Dr. Barnett [Member] | Stock Option [Member]
Number of stock option shares granted					11,130
Stock option exercise price					$ 9
Stock option expiration date					Apr. 24, 2030
Forfeiture shares				11,130
Stock-based compensation expense				$ 24,995
Remaining deferred compensation				56,808
Fair value of stock option vested				$ 81,803	$ 81,803
Dr. Barnett [Member] | Stock Option [Member] | Scenario, Plan [Member]
Number of stock option shares granted	3,710	3,710	3,710
Dr. Barnett [Member] | Barnett Employment Agreement [Member]
Value of options granted to purchase common stock						$ 50,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 18, 2020	Jan. 29, 2020	Jan. 27, 2020	Mar. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Proceeds from sale of stock net of issuance costs						$ 6,000
Subsequent Event [Member] | Lender [Member]
Debt convertible principal amount				$ 2,030
Accrued interest				$ 107
Conversion of convertible debt, shares				41,903
Subsequent Event [Member] | Twenty Sixth Purchase Agreement [Member]
Note principal amount			$ 55,000
Original issue discount, rate			10.00%
Proceeds from sale of stock net of issuance costs			$ 50,000
Shares issuance costs			$ 5,000
Note interest rate			5.00%
Percentage of interest rate increase			18.00%
Note maturity date			Oct. 30, 2020
Debt conversion price per share			$ 0.20
Percentage of lowest closing price			60.00%
Percentage of issued and outstanding common stock			9.90%
Subsequent Event [Member] | Twenty Sixth Purchase Agreement [Member] | January 2020 Note I [Member] | During The Period from The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid			115.00%
Subsequent Event [Member] | Twenty Sixth Purchase Agreement [Member] | January 2020 Note I [Member] | During Months Six Following The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid			120.00%
Subsequent Event [Member] | Twenty Sixth Purchase Agreement [Member] | January 2020 Note II [Member] | During The Period from The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid		115.00%
Subsequent Event [Member] | Twenty Sixth Purchase Agreement [Member] | January 2020 Warrants I [Member]
Warrants term			5 years
Number of warrants to purchase shares of common stock			275,000
Warrants exercise price per share			$ 0.20
Subsequent Event [Member] | Twenty Seventh Purchase Agreement [Member]
Note principal amount		$ 55,000
Original issue discount, rate		10.00%
Proceeds from sale of stock net of issuance costs		$ 50,000
Shares issuance costs		$ 5,000
Note interest rate		5.00%
Percentage of interest rate increase		18.00%
Note maturity date		Oct. 30, 2020
Debt conversion price per share		$ 0.20
Percentage of lowest closing price		60.00%
Percentage of issued and outstanding common stock		9.90%
Subsequent Event [Member] | Twenty Seventh Purchase Agreement [Member] | January 2020 Note II [Member] | During Months Six Following The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid		120.00%
Subsequent Event [Member] | Twenty Seventh Purchase Agreement [Member] | January 2020 Warrants II [Member]
Warrants term		5 years
Number of warrants to purchase shares of common stock		277,500
Warrants exercise price per share		$ 0.20
Subsequent Event [Member] | Twenty Eight Purchase Agreement [Member]
Note principal amount	$ 41,667
Original issue discount, rate	10.00%
Proceeds from sale of stock net of issuance costs	$ 37,500
Shares issuance costs	$ 4,167
Note interest rate	5.00%
Percentage of interest rate increase	18.00%
Note maturity date	Nov. 18, 2020
Debt conversion price per share	$ 0.20
Percentage of lowest closing price	60.00%
Percentage of issued and outstanding common stock	9.90%
Subsequent Event [Member] | Twenty Eight Purchase Agreement [Member] | March 2020 Note [Member] | During The Period from The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid	115.00%
Subsequent Event [Member] | Twenty Eight Purchase Agreement [Member] | March 2020 Note [Member] | During Months Six Following The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid	120.00%
Subsequent Event [Member] | Twenty Eight Purchase Agreement [Member] | March 2020 Warrants I [Member]
Warrants term	5 years
Number of warrants to purchase shares of common stock	208,333
Warrants exercise price per share	$ 0.20
Subsequent Event [Member] | Twenty Nineth Purchase Agreement [Member]
Note principal amount	$ 41,667
Original issue discount, rate	10.00%
Proceeds from sale of stock net of issuance costs	$ 37,500
Shares issuance costs	$ 4,167
Note interest rate	5.00%
Percentage of interest rate increase	18.00%
Note maturity date	Nov. 18, 2020
Debt conversion price per share	$ 0.20
Percentage of lowest closing price	60.00%
Percentage of issued and outstanding common stock	9.90%
Subsequent Event [Member] | Twenty Nineth Purchase Agreement [Member] | March 2020 Note [Member] | During The Period from The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid	115.00%
Subsequent Event [Member] | Twenty Nineth Purchase Agreement [Member] | March 2020 Note [Member] | During Months Six Following The Original Issue Date [Member]
Percentage of outstanding principal balance of note prepaid	120.00%
Subsequent Event [Member] | Twenty Nineth Purchase Agreement [Member] | March 2020 Warrants II [Member]
Warrants term	5 years
Number of warrants to purchase shares of common stock	208,333
Warrants exercise price per share	$ 0.20